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Abstract 
DNA methylation is a powerful epigenetic control mechanism, essential for the 
regulation of transcriptional processes. In mammals, methylation occurs mainly 
at CpG dinucleotides and the modified sequence is recognised by members of 
the methylated DNA-binding domain (MBD) family. Methylated DNA binding 
domain 2 (MBD2) is a 44 kDa protein with the ability to distinguish between 
methylated and unmethylated DNA. It is associated with histone deacetylases 
and nucleosome remodelling complexes in vivo, and functions as a transcrip-
tional repressor. MBD2 expression levels correlate with certain types of cancer 
and MBD2 may contribute to tumour development, by inappropriate silencing 
of tumour suppressor genes. MBD2 is a link between DNA methylation, chro-
matin structure and certain disease mechanisms. Understanding how methylated 
DNA is recognised by MBD2, will help establish its specific role as a methylation 
interpreter. 
This thesis describes the structure determination of the 72 residue MBD from 
mouse MBD2, using solution NMR spectroscopy. The MBD has a characteristic 
wedge-shaped fold, with one face made up of 13-sheets, and the other of an a-helix 
plus a hairpin loop. Loop Li, between two long beta-strands, is much more rigid 
in this structure compared to the equivalent region in other members of the MBD 
family. It appears to be a pre-formed DNA binding loop and overlays well with 
the structure of the MBD (from MBD1):DNA complex, solved by another group. 
NMR was subsequently used to follow the titration of the MBD from MBD2, 
with a 12 base-pair DNA oligomer, symmetrically methylated at a central CpG 
pair. Large chemical shift changes in the '5N-HSQC spectrum were observed for 
Li loop residues, and for an arginine residue at the base of the a-helix. This 
corresponds to the DNA binding interface in the MBD1 MBD:DNA complex 
structure. 
Surface plasmon resonance was used to compare the affinities of three different 
MBDs for DNA oligomers in various methylation states. The MBD2 MBD showed 
weaker binding to symmetrically methylated DNA, when compared to MeCP2 
and MBD4 MBDs. In general, there was no difference in affinity for any of the 
methylated oligomers, and no construct bound unmethylated DNA. There is some 
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In eukaryotic organisms, chromosomal DNA is packaged into chromatin. Chro-
matin is a complex array of helical DNA and many associated proteins, but the 
essential building blocks are repeating nucleoprotein units, called nucleosomes. 
DNA is wound around proteins called histones, which are small, basic proteins 
with a higher than average lysine and arginine content. Individual histones have 
a characteristic 'histone fold' secondary structure, with protruding, charged N-
terminal tails. Two each, of four different histones: H2A, H2B, H3 and 114 form 
an octamer core particle, while histone Hi is known as the linker histone [1]. 
In 1997, the first high-resolution structure of the nucleosome core particle was 
determined: 146bp of DNA wrapped around the histone octamer [2](figure 1.1). 
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Figure 1.1: The structure of the nucleosorne core particle solved to a resolution 
of 2.8A. 146bp of DNA (shown in red and yellow) is wrapped around the histone 
octamer (shown in light blue). Taken from [3]. 
1.1.1 Dynamic chromatin 
Tightly-packed DNA, however, must also be made accessible for the nuclear pro-
cesses which are essential for life, such as replication and transcription. So how 
does the cell manage to effectively package several centimetres of DNA into a a 
few pm, while still retaining its functionality? Chromatin is dynamic and consists 
of more and less densely packed regions, called heterochromatin and euchromatin, 
respectively [4]. Euchromatin is commonly thought of as the "open" state, where 
the DNA sequence is available to be read or recognised or modified. Heterochro-
matin can be divided into two subclasses: Constitutive heterochromatin is found 
around centromeres and telomeres of all somatic cell types, packaging DNA with 
a low gene content. That is to say, there are similar regions in all cells charac-
terised by densely packed chromatin, which makes highly repetitive, non-coding 
DNA inaccessible. 
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Facultative heterochromatin is cell-type dependent, packaging genes that are 
not required for the function of a particular cell or tissue type. This inactive state 
will be passed down the cell lineage. 
Over the years, researchers have established what the features of the different 
types of chromatin are, especially with respect to epigenetic markers. Epige-
netics refers to heritable changes in phenotype, that are not coded for in the 
DNA sequence, but may still be passed on to successive generations by another 
mechanism [5]. Examples of epigenetic heritability include maintenance of DNA 
methylation states after replication and preservation of chromatin architecture 
after cell division. 
1.1.2 Histone modification 
Although histones were once thought to have a purely structural role, they are 
now known to play an active part in regulating biological processes. The N-
terminal tails of histone molecules stick outwards from the surface of the nu-
cleosomes and are the sites of many post-translational modifications including 
acetylation, methylation, phosphorylation and many others (for review see [6]). 
The distinct patterns of such modifications, led in 2001 to the "histone code" hy-
pothesis, which suggests that signals encoded on histone tails are read by other 
proteins to regulate transcriptional states [7]. 
1.1.3 Histone acetylation and chromatin remodelling 
The most extensively-studied histone tail modification, is acetylation. Histone 
acetyl transferases (HATs) and histone deacetylases (HDACs) are the enzymes 
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responsible for catalysing the reversible reaction. Generally speaking, acetylation 
is associated with a more open chromatin state and transcriptional activation. 
Conversely, HDACs are commonly linked to gene silencing and a closed, hete-
rochromatic structure. 
Acetylation may have a direct influence on chromatin structure by neutral-
ising charged residues in the histone tails, thus weakening the DNA-nucleosome 
interaction [7]. However, it has also been shown that acetylated histones can re-
cruit transcriptional activators [8], and that HATs are often part of large protein 
complexes, targeted to promoters [9, 10]. 
HDACs are also commonly found as part of multi-subunit complexes, but 
these are transcriptionally repressive. A number of different pathways exist, all 
featuring the recruitment of HDACs to DNA-binding proteins by intermediate 
factors [11]. The Mi2/NuRD (Nucleosome Remodelling/ HDAC) and Sin3/HDAC 
complexes share a common core comprising HDAC1/2 and histone binding pro-
teins RbAP46/48 [12]. These particular complexes will be described in more 
detail later. Other complexes lacking RbAP46/48 [13], or containing only one 
HDAC unit have also been identified [14], so there seem to be a wealth of pos-
siblities for specific deacetylation-signalled events. Some HDAC complexes even 
display specificity for certain histone tails [15]. 
Chromatin remodelling complexes function in two main ways: either the lo-
cation of the nucleosome on a particular DNA sequence, or the state of the nu-
cleosome itself, may be altered [16]. The histone octamer can be slid along the 
DNA and histone variants (eg. H2A.Z) may be incorporated into the nucleosome 
to change its structure and accessibility. The most important group of enzymes 
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involved in remodeling is the Snf2-like, ATPase/helicase family, of which the 
best characterised subfamilies are SWI/SNF (Switch/Sucrose non-fermenting) 
and ISWI (imitation switch). Both have been shown to activate and repress 
transcription, as part of larger remodeling complexes such as a/BAF and NURF 
[17, 18]. Mi2/NuRD is part of the CHD1 subfamily. It is unable to alter nude-
osomal spacing [19], but as part of the MeCP1 complex (together with MBD2 
and p66/p88) can preferentially remodel and deacetylate methylated nucleosomes 
[20]. Thus, nucleosome remodeling and histone deacetylation are linked to gene 
silencing by methylation. 
1.2 DNA methylation 
DNA methylation occurs at the C5-position of cytosine and functions as a power-
ful epigenetic control mechanism. Methylation at CpG dinucleotides is the most 
abundant covalent modification of the vertebrate genome, but there is a lower 
than expected frequency of CpGs in mammals. This is apart from in small re-
gions of about 1 kilo base-pairs (bp), called CpG islands. These islands have a 
high proportion (50%) of the total unmethylated genomic CpGs, and are often 
located in or around a gene's promoter or first exon. A strong correlation has 
been found between methylation of CpG islands and repression of downstream 
genes, implicating methylation in the maintenance of silent chromatin [21]. 
What is the mechanism by which CpG methylation inhibits transcription? 
Several hypotheses have been proposed, including direct and indirect mecha-
nisms. It was thought that cytosine methylation could exclude the binding of 
transcription factors and so directly silence genes, which is true in a limited num-
ber of cases. However, it is now generally accepted that meCpG recruits specific 
repressors to mediate its effects [1]. 
Studies in Xenopus oocytes have shown that repression of a methylated tern-
plate coincides with nucleosome array formation [22] demonstrating the link be-
tween DNA methylation and chromatin remodelling. Chen et al. showed that in 
plants, the HDAC inhibitor, Trichostatin A, can reactivate silent rRNA genes, in 
a similar manner to 5-aza-dC, the DNA methylation inhibitor [23]. Thus, DNA 
methylation and histone acetylation appear to act synergistically. 
1.2.1 The DNMT family 
Methylation patterns are established and maintained by DNA methyltransferases 
(DNMTs). In eukaryotes, five members of the DNMT family are known. 
DNMT1 is the most abundant methyltransferase in somatic cells and was the 
first to be identified [24]. It has a preference for hemimethylated DNA over un-
methylated DNA, and is targeted to replication foci [25]. Therefore, it is thought 
mainly to be responsible for maintaining methylation patterns after DNA replica-
tion [26, 271. In contrast, DNMT3a and 3b have an equal preference for unmethy-
lated and hemimethylated DNA, and are known as de novo methyltransferases 
[28]. However, the categorisation of the DNMTs into de novo and maintenance 
groups is becoming less rigid. Overexpression of DNMT1 in cancer cells results 
in endogenous CpG island methylation [29], and disrupting the DNMT1 gene in 
somatic cells results in only a 20% decrease in genomic methylation levels [30]. 
Recently, a role for DNMT1 as a positive effector of de novo methylation has 
been described [31]. 
In mice, targeted mutation of Dnmtl has an embryonic lethal effect [32]; 
Dnmt3b knockouts are not viable and Dnrnt3a knockouts die at around one month 
[33]; so the DNMT genes do appear to have some unique functions. 
The DNMT2 protein was first thought to be catalytically inactive, but has 
since been found to methylate DNA at a very low level in vitro [34]. In addition, 
Drosophila and mouse Dnmt2 proteins are both able to methylate cotransfected 
plasmid DNA in transient transfection studies [35]. However, a biological niche 
for DNMT2 has not been found. 
A protein with some homology to DNMT3a and 3b, is the most recent family 
member to be identified. DNMT3L seems to regulate the initiation of maternal 
methylation imprints [36], but is not catalytically active in vitro [37]. A study 
of the interplay within the mammalian DNMT family, has shown an interaction 
between DNMT3L and the de novo methylatransferases Dnmt3a/b [38], while the 
mouse Dnmt3L and Dnmt3a/b proteins are found to associate in vitro [39]. It has 
been suggested that Dnmt3L recruits an active methylase to maternal imprinting 
targets, and that it can also function as a HDAC1dependent transcriptional 
repressor [40]. 
1.3 Introduction to the MBD family 
Once the methylation patterns are in place, how are they recognised to produce 
a change in transcriptional state? 
Methyl-CpG-binding Protein 1 (MeCP1) and MeCP2 were first described as 
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Figure 1.2: Schematic diagram of the five core members of the MBD family. 
Various domains are indicated: MBD in blue; TRD in green; putative coiled 
coil in cyan; Glutamate-rich region in yellow; CXXC domains in red; and the 
glycosylase unique to MBD4 in orange. 
activities that had a specific affinity for methylated DNA. MeCP1 was later shown 
to be a complex, while MeCP2 is a 55kDa protein. A deletion analysis of MeCP2 
identified the minimal region necessary for methylated-CpG (meCpG) binding, 
the methyl-CpG-binding domain (MBD). The MBD is considered a novel DNA-
binding motif and is about 70 residues long. In order to find other MBDs in 
mammals, the expressed sequence tag (EST) database was screened to yield novel 
proteins MBD2, 3 and 4. Together with MeCP2 and previously discovered MBD1, 
these five proteins make up the core MBD family [41]. 
The MBD is the only region of sequence similarity common to all family mem-
bers, and they do not resemble each other outside this domain. The exception 
is MBD2 and MBD3, which are 93% similar and 72% identical over their entire 
length. Aligning the MBDs shows the similarity of MBD1-3 in particular, whilst 
MeCP2 and MBD4 occupy a separate subclass. In spite of the general differences, 
an intron is found at a conserved position in all the MBD genes. Also, several 
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Figure 1.3: A multiple sequence alignment of the MBDs of various MBD family 
members, numbered as for mouse MBD1. Amino acids are coloured by residue 
type and conservation, which is also summarised by the black quality curve. The 
alignment was done with MUSCLE [42], and the plot created with ClustaiX [43]. 
family members have a transcriptional repression domain (TRD), highlighting 
another common in vivo function. A brief description of each family member is 
given below. 
1.3.1 MeCP2 
MeCP2 has been very well characterised owing to its link with Rett syndrome 
[44]. It can bind one meCpG [45], distinguishing it from the MeCP1 complex, 
which requires 12 meCpGs for binding [46]. It has a large TRD and functions as a 
transcriptional repressor through its association with the Sin3a/HDAC complex 
[47, 48]. However, this is not a stable interaction and MeCP2 is likely to act 
through other repressive pathways [49]. A recent study has shown that MeCP2 
displays some sequence selectivity in DNA binding, requiring AT bases adjacent 
to the meCpG [50]. 
1.3.2 MBD1 
MBD1 is the largest member of the family (70kDa), and is known as a 
methylation-dependent transcriptional repressor, due to its C-terminal TRD. As 
well as the MBD, it has a variable number of CXXC motifs, depending on alter-
native splicing. One of these motifs has been shown to bind unmethylated CpG 
sites in vivo. Although it was originally identified as the MBD activity of MeCP1 
[51], this has now been shown not to be the case [52]. MBD1 forms a stable 
complex with SETDB1, a histone H3:K9 methyltransferase, and is responsible 
for its recruitment to chromatin assembly factor CAF1 [53]. 
1.3.3 MBD2 
MBD2 exists as two isoforms, produced by initiation at one of two methion-
me codons. MBD2a is 43.5kDa protein, characterised by repeated glycine and 
arginine residues at the N-terminus, which is probably unstructured. MBD2b 
(29.1kDa) lacks the first 140 amino acids of MBD2a, and starts at the MBD. 
MBD2 has an overlapping MBD and TRD, and is associated with HDAC1 in 
mammalian cells. It acts as a transcriptional repressor and is the true MBD com-
ponent of the MeCP1 complex [52]. Reported demethylase activity for MBD2 
[54] has not been reproduced in other research groups [55, 52]. 
1.3.4 MBD3 
MBD3 is about 70% identical to MBD2. However, the mammalian protein differs 
at two amino acids within the MBD making it incapable of binding methylated 
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Figure 1.4: Alignment of the MBD2b and MBD3 proteins from mouse. The 
numbering is as for MBD2b and the key is the same as for figure 1.3. 
nature of the differences and the implications for mCpG recognition will be dis-
cussed later. MBD3 has many splice forms, the most common of which is a 32kDa 
variant. 
1.3.5 MBD4 
MBD4 has a function distinct from the other family members. In addition to 
the MBD it has a second DNA binding domain at the C-terminus. The G:T 
mismatch-specific DNA glycosylase domain is responsible for the ability of MBD4 
to efficiently recognise and remove T from a G:T mismatch, and U from a G:U mis-
match [56]. MBD4 is similar in function to the thymine-DNA glycosylase (TDG) 
enzyme, despite a complete lack of sequence homology. The crystal structure of 
the glycosylase domain has been solved, and shows that it belongs to the helix-
hairpin-helix DNA glycosylase superfamily [57]. MBD4's MBD prefers 5-methyl 
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CpG paired with TpG, compared to symmetrically methylated CpGs. However, 
the MBD does not influence the specificity of the glycosylase activity for G : T 
mismatches [58, 591. As the G:T mismatch is the expected product of deaminat-
ing one side of meCpG, MBD4 has been designated a repair enzyme specific for 
methylated DNA. MBD4 has also been shown to interact with MLH1, a protein 
implicated in mismatch repair. 
1.3.6 More mammalian MBDs 
Methyl-CpG-Binding domains have also been found in 6 additional human pro-
teins. A BLAST search of protein domain family databases (eg. Pfam, Smart) 
using the MBD of MeCP2, revealed two novel proteins and 4 known ones (in-
cluding SETDB1). Most of these proteins have been linked to regulation of gene 
expression, but their ability to bind methylated CpGs is unknown [60]. 
1.3.7 Kaiso 
Kaiso is a methyl-CpG binding protein with a difference. Rather than an MBD, 
it uses a zinc-finger motif to recognise its preferred sequence of two consecutive 
mCpGs [61]. It also s as a methylation-dependent transcriptional repressor. 
1.4 MBDs in other organisms 
1.4.1 MBDs in plants 
In plants, epigenetic control is mediated by cytosine methylation at both CpG 
and CpNpG sequences. To date, 12 putative MBD proteins have been identified 
12 
in Arabidopsis thaliana, of which 3 have been shown to bind specifically to sym-
metrically methylated CpGs. These also happen to be those with MBD motifs 
most similar to the human forms. Of these, AtMBD7 is unique in that it con-
tains two MBDs, and AtMBD6 is associated with HDAC activity [62]. Work by a 
second group has revealed subtle differences in the specificity of AtMBD5 and 6: 
While MBD5 could bind a symetrically or hemimethylated probe, MBD6 could 
only form a complex with symmetrically methylated DNA [63]. None of the pro-
teins bound methylated CpNpG sequences in either study [62, 63]. Recent efforts 
have shown the interaction of AtMBDs with the chromatin remodelling factor 
DDM1 (decrease in DNA methylation 1) [64]. It has been proposed that the 
DDM1-AtMBD interaction may constitute a plant complex, similar in function 
to mammalian MeCP1. 
1.4.2 Nematode MBDs 
Little is known in general, about DNA methylation in nematodes, but the C. 
elegans genome is completely free of methylation. A dnmt2 gene was found in 
P. pacificus, and the protein product is 30-40% identical to DNMT2 from D. 
melanogaster and mouse. However, there is no evidence for DNA methylation 
in this species either, and dnmt2 morpholinos, or depletion of dnmt2 by RNAi, 
produced no discernable phenotype. An mbd-2 gene is present in C. elegans, C. 
briggsae and P. pacificus, albeit with different sequences and gene structure. All 
the nematode MBD2 sequences analysed lacked a typical MBD, which might be 
expected due to the lack of methylation in their genomes. However, MBD2 RNAi 
phenotypes are distinctive. The most severe of these included paralysis and early 
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death in C. briggsae [65]. This could indicate a role for MBD2 that is unrelated 
to DNA methylation. 
1.4.3 MBD2/3 in insects 
Drosophila melanogaster has no detectable 5mC in the adult genome, but embry-
onic DNA is methylated at very low levels [66]. A Drosophila protein homologous 
to the mammalian MBDs has been found, which is 56% similar to MBD2 and 73% 
similar to MBD3. It exists in two forms: dMBD2/3 and a shorter splice variant, 
dMBD2/3. cDNA for MBD2/3 and MBD2/3L\ has also been isolated from the 
cricket (Acheta domesticus), which does have a methylated genome. The cricket 
proteins are more closely related in sequence to the mammalian MBDs than to 
dMBD2/3, and aMBD2/3 specifically binds methylated DNA [67]. Two studies 
in Drosophila showed no detectable methyl-CpG binding by MBD2/3 [67, 68], 
but in a third study, weak binding was observed [69]. It seems unlikely that 
dMBD2/3 would have this capability. There is both a 20 amino acid insertion, 
and a deletion in its MBD which would significantly disrupt the domain fold. The 
flexible loop, Li, would be hugely extended, and the c helix deleted - both are 
essential structural features of the MBD. It has been proposed that the role of 
dMBD2/3 is in developmental regulation, where it functions as a corepressor to 
silence specific genes [68]. The long-form appears in the cytoplasm in early em-
bryogenesis. It then enters the nucleus at a stage which coincides with increased 
genomic activation and peak-level DNA methylation. Later still, MBD2/3A is 
the predominant form [70]. dMBD2/3 can associate with dHDAC1 and dMi-2, 
so it could be a component of DrosophilaNuRD-like complex [67]. 
14 
	
53 	 MIZF 	 154 	211 P66 
I I I 
69 	 217 239 
1 	 • 1262  
II 
27P66 45 	 209 
L 
27 TRD  82 
Figure 1.5: Diagram to show the regions of MBD2b that interact with various 
proteins and protein-complexes 
1.5 MBD2 interactions 
The focus of this thesis is MBD2, so it is important to look in more detail at the 
specific interactions and functions of this protein. A number of different MBD2 
binding partners have been discovered, and are described below (see figure 1.5). 
1.5.1 MBD2-MBD3 complex 
MBD3 has been reported to form a complex with MBD2. Since the MBD2-
MBD3 complex was shown to have a preference for hemimethylated DNA, it is 
thought to be targeted to replication foci, to establish transcriptionally repressive 
chromatin. MBD2 and MBD3 were both shown to homodimerise, and to form 
heterodimers together. In the case of MBD2b, this most likely involves both 
N- and C-terminal domains, in particular the MBD and the predicted coiled-
coil [71]. This interaction suggests a potential role for MBD3 in maintaining 
transcriptionally repressed chromatin. 
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1.5.2 The Sin3 and NuRD complexes 
Sin3 is a large multidomain protein found in yeast, Drosophila and higher ver-
tebrates. It has four, highly conserved imperfect repeats, which are predicted to 
fold into paired amphipathic helix (PAH) domains, connected by flexible linkers. 
Sin3 is thought to function as the foundation of large repressive complexes, with 
multiple components. Small variations in the subtype and stoichiometry of these 
components tailor Sin3 to its various functions in different species. MeCP2 and 
MBD2 have both been shown to recruit the Sin3 complex; MBD2 binds to the 
PAH3 of Sin3 variant Sin3A, through a short region (aa. 27-82) which overlaps 
the MBD, (see figure 1.5). Because this region was also the minimum needed 
for efficient transcriptional repression, it is termed the TRD [55]. MeCP2 has 
a C-terminal TRD [47], which is also capable of mediating a repressive effect 
through Sin3A [48, 72]. The Nucleosome Remodelling/ H DAC (NuRD) complex, 
also known as Mi-2, is a 2MDa complex found in mammals, Xenopus and proba-
bly also in plants. The NuRD and Sin3 complexes share a common core of HDACs 
1 and 2, and histone binding proteins RbAp48 and 46. Each complex also con- 
tains three other polypeptides. These are Mi-2, MTA2 and MBD3 in NuRD; and 
Sin3A, and its associated proteins SAP30 and SAP18 in the Sin3 complex. The 
ATP-dependent nucleosome-remodelling activity of NuRD is due to Mi-2, which 
belongs to the CHD subfamily of SWI2/SNF2 DNA helicases/ATPases. Another 
feature of NuRD is metastases associated protein 1 (MTA1) or the similar protein 
MTA2. However, MTA1 is of an unknown biochemical function. 
Both MBD2a and MBD2b interact with NuRD, although the former is a 
more efficient association. The mammalian NuRD complex does not bind to 
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methylated DNA on its own, but MBD2a can tether NuRD to methylated DNA 
[73]. MBD3 copurifies with NuRD, and has been shown to interact with MBD2. 
It is thought that the MBD2-MBD3 interaction may be the mechanism by which 
NuRD is tethered to methylated DNA. 
1.5.3 MeCP1 and p66 
MBD2 has been identified as a component of the MeCP1 complex [52], which 
contains Mi2/NuRD and two additional polypeptides, p66 and p68. However, it 
is not known which of the MeCP1 components binds directly to MBD2. Two 
mammalian proteins, homologous to the p66 component of the Xeno pus NuRD 
complex, were identified as MBD2b binding partners. One of these, hp66a , is 
orthologous to the p66 component of Mi-2/NuRD, whilst hp660 is identical to p66 
of MeCP1. MBD2 and hp66a colocalise in the nucleus, where hp66a functions 
as a potent transcriptional repressor [74]. There are two regions on MBD2 which 
specifically bind hp66a: A region from amino acids 27 to 45, termed ID1, and a 
region from 211 to the very C-terminus (termed 1D2), see diagram 1.5. p66/p88 
have a GATA-type zinc-finger domain and two highly conserved regions. CR1 is 
involved in the association with the MECP1 complex, while CR2 is needed for 
localising p66/p68 and MBD3 to specific loci [75]. 
Both p66ce and 0 also bind MBD3 [74]. 
1.5.4 MIZF 
The transcriptionally repressive effect of MBD2 is enhanced by MIZF, a 60kDa 
novel zinc finger protein. This occurs in an HDAC-dependent pathway, although 
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MIZF can't associate directly with HDACs. The interaction between MBD2 
and MIZF was identified in a yeast two-hybrid screen, then confirmed by IP 
experiments and and in vitro binding studies. Although MIZF has 7 zinc finger 
domains similar to the C2112 type (found in numerous TFs [76] and KAISO [77]), 
only fingers 4 to 7 are necessary for MBD2 binding. This lies in the region between 
amino acids 53-154 [78] (see figure 1.5). 
MIZF acts as a negative regulator of Rb expression, and so may inhibit myo-
genic differentiation [79]. Could MBD2 be involved in this process? MIZF binds 
to a specific sequence in the gene's promoter, requiring zinc fingers 1-4 and 7 
[80]. However, this does not happen in a methylation dependent manner, despite 
the presence of at least one CpG. The consensus MIZF binding sequence is also 
found upstream of the GSTP1, p14/ARF and p16/INK4a genes, which are all 
selectively associated with MBD2 [81, 82]. Therefore, cooperation between the 
two proteins to control gene silencing is a possibility. 
1.5.5 MBDin 
In contrast, a 374a.a. protein called MBDin relieves MBD2-mediated transcrip-
tional repression in transient transfection assays. The C-terminal 53 a.a.s of 
MBD2 are sufficient for this interaction [83]. MBDin was found to be identical to 
XAB1 (XPA binding protein 1), a cytoplasmic GTPase and the interaction part-
ner of the DNA repair enzyme, Xeroderma Pigmentosum group A protein (XPA) 
[84]. In co-IP experiments, XPA was detected with anti-MBD2 antibodies, but 
only in the presence of MBDin, so perhaps it acts as a bridge between the two? 
Although MBD1n/XAB1 is mainly cytoplasmic, the protein contains a potential 
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nuclear export signal (NES) and has been detected in the nucleus, co-localising 
with MBD2 to major satellite DNA. It is able to re-activate MBD2-mediated re-
pression of promoters in this densely-methylated region, without altering methy-
lation patterns. This could constitute a link between DNA methylation and nu-
cleotide excision repair (NER) systems, similar to the MBD4-MLH1 interaction 
for mismatch repair [85]. 
MBDin/XAB1 does not appear to act via a mechanism like that of the dis-
placement of MBD2 by GATA-3 in IL-4 induction [86], where there is direct 
competition between the two proteins. The presence of MBD2 actually improves 
gene reactivation by MBDin/XAB1, so perhaps MBD2 is recruited by MBDin, 
to block an otherwise repressive pathway. 
1.6 MBDs and disease 
There are a number of different associations between MBD proteins and human 
disease. The most intensively studied is the mutation of MeCP2 and Rett syn-
drome, a neurodevelopmental disorder. Mutations are mainly found in the MBD, 
TRD and C-terminus, and are thought to interfere with methylation-dependent 
transcriptional silencing. MeCP2 is now also thought to regulate neuronal gene 
expression and the formation of new synaptic connections. 
The link between MBD mutations and autism has been investigated [87]. 
Apart from the occurance of MeCP2 polymorphisms in some autistic patients, 
no clear link between the MBD family and autism could be found. 
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1.6.1 MBDs and cancer 
A relatively new area of investigation is into the connection between the MBDs 
and human cancer. Tumour development in humans is associated with a change 
in methylation pattern: DNA of cancerous cells exhibits local hypermethylation 
at CpG islands, whereas the rest of the genome is globally hypomethylated [88]. 
It is not clear which comes first. Is methylation of CpG islands the cause of 
transcriptional silencing or do genes become methylated after being silenced by 
another process? In embryonic cells, gene silencing precedes de novo methylation, 
so DNA methylation is thought to maintain the inactive transcriptional state 
rather than establish it (discussed in [89]). 
However, the role of MBDs in cancer progression is unclear due to conflicting 
evidence about their effects. This is illustrated by the volume of knowledge about 
Iv:4,_pJ 
MBD2 has been shown to associate with the aberrantly methylated, regula-
tory ends of the p14 and p16 tumour-suppressor genes. It is thought to exert a 
repressive effect through a histone deacetylase-dependent pathway [81], and so 
silence this locus in colon carcinomas. Could these tumour-supressor genes be 
reactivated by the deletion of MBD2? 
Transcriptional silencing of the ir-class glutathione S-transferase, GSTP1, is 
mediated by MBD2. This gene is commonly inactivated by somatic CpG island 
hypermethylation, in prostate, liver and breast cancers [90]. 
MBD2 has been implicated in the failure of mice with adenomatous polyposis 
coli germ-line mutations (APCMmn), to survive (see figure 1.6. APCMmn mice are 
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Figure 1.6: A survival curve of APCM  mice, for three different Mbd2 genotypes. 
Figure taken from [91]. 
and show much better survival rates. The heterozygotes show a survival pattern 
halfway between that of the wild type and nulls, so the concentration of MBD2 
appears to be proportional the effect [91]. 
MBD2 deficiency also does not accelerate lymphomagenesis in p53-null mice. 
In contrast, when DNMT1 is deleted, there is increased tumorigenesis and ge-
nomic instability [92]. Methylation interpreters are therefore better potential 
candidates for drug targets. However, there is evidence to suggest that deregu-
lation of MBD2 itself occurs in some cancers. Breast carcinomas can be divided 
into two groups based on their expression level of M8D2; MBD2 mRNA levels 
are significantly associated with tumour size in invasive ductal carcinomas [93]; 
and a reduction in MBD2 rnRNA expression was found in colorectal and gastric 
cancerous tissues [94]. Finally, a significantly reduced risk of developing bladder 
cancer is associated with high levels of MBD2 expression, demonstrating a protec- 
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tive role for MBD2 [95]. These observations will only be reconciled when we have 
a better grasp of the underlying mechanisms of cancer epigenetics. One recent 
study has found that oxidative DNA damage in the methylated MBD recognition 
sequence, can reduce MeCP2 binding by an order of magnitude [96]. By lower-
ing the ability of MeCP2 to distinguish between methylated and non-methylated 
sites, DNA damage might result in expression of normally silent genes. The same 
group has also investigated the effect of halogenation at the 5 position of cyto-
sine, which enhances binding of the MeCP2 MBD to DNA.[97]. These halogens, 
produced by inflammatory processes, may then act as false methylation initiation 
signals. By recruiting DNMTs and other machinery, the aberrant methylation 
patterns so characteristic of cancer, might be produced. 
1.7 MBD structure 
1.7.1 Comparison of MBD folds 
The MBDs of both MeCP2 and MBD1 have been solved by NMR [98, 99]. Al-
though the MeCP2 construct used for structure determination was larger, the 
ordered portion corresponds to 69 MBD residues that overlap with the MBD1 (1-
75) structure. The domain from both proteins has the same basic wedge-shaped 
c/3-sandwich fold, shown in figure 1.7. One face of the wedge is made up of a 
twisted 3-sheet and is extended by a flexible loop. The other side is an a-helical 
region in MeCP2 and an of-helix plus hairpin loop in MBD1. 
The fold has a well-defined hydrophobic core, and several well-conserved hy-
drophobic residues such as Leull, Trp15, Leu49, Phe62 and Phe64 (MBD1 num- 
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MeCP2 MBD 	 MBD1 MBD 
Figure 1,7: A comparison of the MeCP2 and MBD1 MBDs in solution, showing 
a common fold. A cartoon of each MBD in a similar orientation is shown. Sec-
ondary structure elements are numbered and displayed as arrows (/3-strands) or 
ribbons (a-helices) and the long loop is denoted Li. MeCP2 has a longer a-helix 
and lacks the C-terminal hairpin loop. 
bering) are common to both structures. Tyr34 and Tyr52 are also highly con-
served and have solvent exposed aromatic rings in both structures. Several basic 
residues are found grouped together on one side of the molecule; a surface made 
up of Arg30, Arg42, Arg44, Lys46 and Lys65; and Arg22 and Lys23 in the Li 
loop. In both structures, the flexible Li loop has few long-range NOEs. This is 
perhaps surprising as its residues are well-conserved amongst MBD family mem-
bers. Heteronuclear NOE values are smaller in the loop residues compared to the 
well-defined regions on either side. 
In the MBD1 structure, the hairpin loop is held together by a main-chain 
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Figure 1.8: The structure of the MBD from MBD1, with the backbone shown in 
black. The side chains of certain residues are coloured: arginines and lysines in 
red; aromatics in blue; aliphatics in green and Asp63 in purple. The position of 
G1y67 is indicated with a red line, and the hydrogen bond between it and Asp63, 
is shown by a black dotted line. The molecule has been rotated by 25° between 
each depiction. 
hydrogen bond between G1y67 HN and Asp63 carbonyl. The two C-terminal 
phenylalanines, Phe62 and Phe64, are important for forming contacts with the 
rest of the molecule to stabilise the orientation of the hairpin. Substitution of 
Phe64 with Ala in MBD1 disrupted folding and DNA-binding activity. Deletion 
of residues 157-162 in MeCP2 (which corresponds to 64-69 in MBD1), causes 
a complete loss of methyl-CpG-binding ability. This hairpin is not present in 
the MeCP2 structure, but the C-terminus still plays an important role in fold 
definition. 
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1.7.2 MBD:DNA complex 
The structure of the MBD1 MBD in complex with methylated DNA has also 
been solved by NMR [100] (see figure 1.9). A construct comprising residues 1-
75, was combined in an equimolar ratio with a 12bp symmetrically-methylated 
oligonucleotide. In the complex, the MBD has a similar fold to the free domain, 
and most of the structure is unaltered by DNA binding. Major structural changes 
do occur in loop Li however, which becomes much more rigid and adopts a 
hairpin-like shape. Li heteronuclear NOE values increase, so as to be comparable 
with those found in the more permanently structured regions. This difference is 
due to seven out of nine residues in the loop, which form mainly hydrophobic 
contacts and hydrogen bonds with one strand of the DNA duplex. The second 
strand is bound by the N-terminal end of the oz-helix, and loop L2, which is 
inserted into the major groove. Base contacts are made by the side-chains of L2 
residues, whilst the helical residues interact with the backbone. 
1.7.3 MeCpG recognition 
In the MBD1:DNA structure, specific recognition of the meCpGs is due to a 
'hydrophobic' patch made up of 5 residues. One methyl group is recognised by 
the side chains of Va120, Tyr34 and Arg22, while the other is contacted by Arg44 
and Ser45 side chains (see figure 1.10). With the exception of Va120, mutation of 
these residues, which are highly conserved throughout the MBD family, results 
in reduced or abolished DNA binding [100]. 
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Figure 1.9: The MBD1 MBD in complex with methylated DNA. The figure was 
produced from coordinates in the Protein Data Bank (PDB) [101], code 11G4. 
The protein is shown as a cartoon, in a similar orientation to those in figure 1.7. 
The DNA is in ball and stick form with the methylated cytosines highlighted in 
red. 
1.8 Project aims 
The aim of this project is to better understand the particular role of MBD2 
in methylated DNA binding. Although the MBD sequence is well conserved 
throughout the family, the proteins have distinctive functions. Many of those are 
due to regions of the protein outside the MBD, and will not be addressed here. 
However, it remains to be discovered if there are differences in the methylated 
DNA binding mechanism of the various family members. Previous structural 
work on the family has almost exclusively employed NMR. Apart from the MBDs 
of MBD1 and MeCP2 mentioned earlier, the matrix attachment region-binding 
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domain of chicken MeCP2, which has an MBD-like fold [102], was also solved by 
NMR. The exception is the glycosylase domain of MBD4 [57], which is a crystal 
structure, but it has a completely different fold. The free MBD is likely to be too 
flexible to form crystals, but due to the more rigid structure formed upon DNA 
binding, it may be possible to crystallise the MBD:DNA complex. The areas of 
investigation in this project are summarised by the following objectives: 
. To determine the structure of the MBD from MBD2 by NMR. 
To study the DNA-binding interface of MBD2 using NMR or X-ray crys-
tallography, or both. 
To investigate the ability of MBDs to discriminate between DNA with a 
single, central CpG, methylated to different degrees. 
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Figure 1.10: The MBD-DNA interface, with the DNA in beige, apart from cy-
tosines in red. Methyl groups are shown in orange. The protein backbone is shown 
in dark green. The 5 key residues involved in meCpG recognition are coloured 
and labelled accordingly. Asp32 (bright green) forms an important salt-bridge 




This chapter describes the production of protein and protein:DNA samples for a 
variety of investigative techniques. The method for producing the MBD2 MBD 
for NMR is described in detail, as it is the basis for the majority of the work 
done. Variations on this method were used to produce other samples. 
2.2 Plasmid description 
DNA corresponding to amino acids 153-224 of mouse MBD2a, (1-72 of MBD2b) 
had previously been cloned into the pET6H vector [103], by Andrew Free at 
The University of Edinburgh. The expressed construct has a total of 80 residues 
and includes an N-terminal 6 histidine purification tag and two additional non-
native residues (MHHHHHHA). The theoretical mass of the construct is 9.1kDa 
as calculated using the EXPASY website [104]. The MeCP2 construct was derived 
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from DNA corresponding to residues 76-167 from rat MeCP2, and cloned into 
the pET6H vector [103] by Andrew Free. The expressed construct has a total 
of 100 residues and includes an N-terminal 6 histidine purification tag and two 
additional non-native residues (MHHHHHHA). DNA corresponding to residues 
63-141 of mouse MBD4, including a C75S mutation, was cloned into the pET30b 
vector (Novagen) by Brian Smith and Julia Boyd at The University of Edinburgh. 
The expressed construct has a total of 125 residues and includes an N-terminal 6 
histidine purification tag and 46 additional residues from the pET30 sequence. 
MBD native vector total Mw (kDa) PT 280nm 
residues residues  
mouse MBD2 1-72 pET6H 80 9.1 9.9 9530 
rat MeCP2 76-167 pET6H 100 11.4 9.8 10810 
mouse MBD4 63-141 pET30b 125 13.8 9.3 8250 
Table 2.1: A table of the protein contructs used, along with theoretical values for 
molecular weight (Mw), isoelectric point (p1) and extinction coefficient at 280nm 
(6280nm), calculated using the EXPASY{104] tool ProtParam. 
DNA for all constructs was provided by Adrian Bird's group at the Wellcome 
Centre for Cell Biology, The University of Edinburgh. A summary is given in 
table 2.1. 
2.3 Transformation 
Constructs were provided as minipreps (plasmid DNA in water or buffer), stored 
at -20°C. E. coli BL21 (DE3) pLysS cells (Novagen) were made competent using 
either calcium chloride [105], or TSB methods (see Appendix A). The cells were 
then transformed with 1il of a 1:10 dilution of plasmid miniprep (approx. 0.5pg 
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DNA). After a final incubation step (37°C for 1 hour), the cells were plated out 
on agar with appropriate antibiotic selection. Chloramphenicol selects for pLysS 
cells [106], kanamycin for pET30b and ampicillin for pET6H plasmids. 
After incubation, single colonies were picked from which to grow overnight 
cultures for protein expression. Fresh stocks of plasmid were also prepared from 
overnight cultures, using the Spin Miniprep kit (Qiagen). Instructions supplied 
with the kit were followed; plasmid DNA was eluted from the preparation columns 
with deionised, autoclaved water. 
Fresh (previous day) transformations were always used for protein expression 
as older transformations were suspected to be linked to sample instability. 
2.4 Protein expression 
Protein samples were made from 0.5-2L of culture, depending on expression levels. 
Each 500m1 of Luria-Bertani (LB) growth medium was inoculated 1:50 with an 
overnight culture of E. coli cells, using appropriate antibiotic selection. The incu-
bation temperature was 37°C and cells were shaken at 200rpm. Cell density was 
measured by the absorbance at 600nm (A600) on a UV/visible range spectropho-
tometer (Lambda 20, Perkin Elmer). Once the A600 reached between 0.5 and 0.6, 
(when cells are typically in log phase growth) protein expression was induced by 
the addition of 1mM isopropyl-/3-D-thiogalactopyrafloSide (IPTG, Sigma) [107]. 
Cell density was monitored regularly during the protein expression phase as 
an indicator of cell health. The expression time was typically 5 hours, and not 
more than 6 hours, to give the maximum, high-quality yield. Cells were harvested 
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immediately if a decrease in A600  was measured, but this was not usually observed 
during growth times of less than 6 hours. 
Cells were harvested by centrifugation (Beckman Coulter) at 15,000g for 
15mins. The supernatant was discarded and the cell pellet transferred to Falcon 
tubes before being spun again in a benchtop centrifuge at 3,000rpm for 10mins, 
to compact the pellet as much as possible. The supernatant was again removed 
and the pellet weighed. At all stages after harvesting, the cells were kept cold, at 
4°C. A typical yield produced 4.5g cells/L and the pellet may be stored frozen at 
-20°C for several months. 
2.4.1 Isotopically labelled samples for NMR 
Isotopically labelled samples were produced as described in section 2.4 above 
except LB media is replaced by M9 minimal media. Minimal media must be 
supplemented with iron, zinc, and sources of carbon and nitrogen. This allows 
samples to be labelled with stable, NMR-active isotopes. Either '5NH4C1 (and 
unlabelled glucose) can be added to make a '5N-labelled sample, or both '5NH4C1 
and '3C-labelled glucose to make a double-labelled sample. Recipes and experi-
mental details are shown in Appendix A. Subsequent harvesting and purification 
steps are the same for all samples. 
2.4.2 Cell lysis 
Harvested cell pellets were resuspended in Bugbuster detergent (Novagen) to dis-
rupt the cell membranes, causing the cells to lyse. Benzonase nuclease (Novagen) 
was added to digest nucleic acids, which made resuspension easier. The cell lysate 
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was kept cold and Complete Mini EDTA-free protease inhibitors (Roche) were 
added - both help to prevent the degradation of the protein. Resuspension was 
carried out for 20-30mins on a rotating wheel or rollers, until the lysate was 
homogeneous and free of large clumps of cells. 
The lysate was then transferred to centrifuge tubes and spun at 50,000g for 
30mins. Protein expressed from all three MBD constructs, is predominantly found 
in the soluble cell fraction, with a negligible amount in the insoluble fraction. Due 
to this fact, the supernatant was removed and the pellet discarded. 
2.4.3 SDS-PAGE 
Proteins were separated and analysed using sodium dodecyl sulphate polyacry-
lamide gel electrophoresis (SDS-PAGE). SDS is an anionic detergent, molecules 
of which wrap around, denature and confer a negative charge on a protein, in 
proportion to its length. Separation occurs in an electric field, produced by ap-
plying a current to the polyacrylamide gel, a porous matrix. Thus, in SDS-PAGE, 
proteins become negatively charged rods, which migrate through the gel towards 
the anode. Migration distance is inversely proportional to the logarithm of mass 
of the protein [108]. MBD proteins were separated on 15% polyacrylamide gels, 
run at a constant 200 Volts for 45 minutes, or until the dye front had run off the 
gel. Proteins were visualised by staining with Coomassie blue (for protocols see 
[109]). Typical gels are shown in figures 2.1 and 2.6. 
33 
2.5 Purification 
Due to the requirement for high levels of purity in an NMR sample, the MBD 
purification strategy is a three-step process. It was originally devised by Dr. 
Andrew Free and optimised in our group. 
2.5.1 Nickel-affinity purification 
The N-terminal, 6 histidine tag (present in each construct), was used to affinity-
purify the protein by nickel chelation [110]. 2-3cm nickel- nitrilotriacetic acid resin 
(Ni-NTA, Qiagen) was poured in Econopak columns (BioRad) for this purpose. 
Immobilised nickel in the NTA column resin coordinates the histidines, while 
proteins without multiple histidines wash through. The supernatant from cell 
lysis was made up to 1mM 3-mercaptoethanol (to prevent oxidation and protein 
aggregation) and 10mM imidazole (to minimise non-specific binding). It was then 
applied to the Ni-NTA column. EDTA-free protease inhibitors were used earlier 
because EDTA, a divalent metal cation chelator, will compete with the histidine 
tag for nickel sites in the resin. 
The column was then washed with binding buffer (50mM NaPi pH 8.0, 300mM 
NaCl), followed by increasing concentrations of imidazole in binding buffer. Imi-
dazole competes with the histidine side chain for Ni-chelation until the histidine-
tagged protein is eventually eluted (in this case at a concentration of 250mM 
imidazole). Following elution from the Ni-NTA column, dithiothreitol (DTT) 
was added to the protein solution to a final concentration of 5mM. The sample is 
80% pure at this stage, but is still contaminated, for example by high molecular- 
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Figure 2.1: An SDS-PAGE gel showing MBD2 MBD protein present in each 
fraction collected from the Ni-NTA purification column. Fractions are: lysate 
(L), flow-through (FT), 4 washes (W), eluate (E) and Vivaspin concentrator flow-
through (V). Broad range protein markers (NEB), are denoted by M, and selected 
molecular weight standards are labelled. The need for further purification steps 
is clear due to contamination of the eluate by several bands of high molecular 
weight (at around 66.4 kDa). 
weight E. coli proteins with a high histidine content (see figure 2.1). 
2.5.2 Ion-exchange chromatography 
Ion-exchange chromatography [111] was carried out using a fast protein liquid 
chromatography (FPLC) system (Amersham Akta), controlled by an associated 
computer and UNICORN (v.2.01) software. A cation-exchange column, Fractogel 
(SO4)2 (Merck), in 50mM Tris pH 8.0, was used to purify the MBD. Buffer-
exchange into a solution of lower salt concentration was not necessary due to the 
high affinity of the MBD for the Fractogel matrix at this pH (See p1 values in 
table 2.1 above). The protein was eluted from the column using a salt gradient 
from 0-1.5M NaCl, achieved by gradually combining 50mM Tris, 2M NaCl pH 
8.0 with the running buffer. A typical elution profile is shown in figure 2.2. 
















Figure 2.2: An ion-exchange trace of the MBD2 MBD (in blue), as determined 
by absorbance at 280nm. The change in conductivity, due to the linear (0-1.5M) 
NaCl gradient, followed by a 2M NaCl wash, is shown in brown. 4m1 fractions 
were collected, the divisions of which are shown in red. 
contributing to the elution peak were combined, and then concentrated using 
20m1 Vivaspin concentrators with a 5kDa Molecular Weight cut-off (VivaScience). 
These were spun at 4,000rpm in a bench-top centrifuge, until the required volume 
was obtained. DTT was then added to a concentration of 5mM. 
2.5.3 Purification by gel filtration 
The protein was further purified by size exclusion [111], using a Superdex 75 gel 
filtration column (Pharmacia). This may be done in the buffer of choice for the 
next stage, for example 50mM NaPi, 50mM NaCl pH 7.0 (filtered and degassed) 













Figure 2.3: A gel filtration trace of the MBD2 MBD, as determined by absorbance 
at 280nm. Overlaid in different colours are successive runs of the same sample. 
Run 1, magenta; 2, red; 3, blue; 4, grey; 5, brown. 0.25m1 fractions were collected, 
shown as red divisions along the x-axis. 
and care was taken to avoid over-loading the column with too much protein, 
resulting in sample loss. Typically, imi of 2mM protein was purified by FPLC in 
up to five runs. An elution profile for the MBD2 MBD is shown in figure 2.3. 
2.6 Final sample preparation 
The final stage in sample preparation was to combine the peak fractions of the 
multiple gel filtration runs. These were concentrated using a 6m1 Vivaspin tube 
(VivaScience) spun at 4,000rpm in a bench-top centrifuge, until the desired vol-
ume ('-'.'200p1) was reached. An estimate of the sample concentration may be 
obtained by measuring its absorbance at 280nm (A280). The theoretical extinc- 
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tion coefficient (see table 2.1) can then be used to calculate the concentration 
according to Beer's Law. It was most efficient to do this immediately before the 
final concentration step, even though a tiny amount of protein may have been 
lost in the concentration process. Yields for the MBD2 MBD construct after the 
ion-exchange step were 15mg/L in LB media and 30mg/L in M9 minimal media. 
2.7 NMR samples 
To achieve the greater level of purity required for NMR samples, only the central 
gel filtration fractions were combined (e.g. fractions C15 to D10 in figure 2.3). 
Vivaspin columns for the final concentration step were thoroughly washed with 
water and then NaPi NMR buffer, to remove any trace of glycerol from their 
membranes. If it was suspected that the sample had become contaminated with 
small molecules such as glycerol, the Vivaspin columns were thoroughly rinsed to 
achieve at least a 1000-fold dilution of any contaminants. After concentration, the 
protein sample was removed from the Vivaspin column and spun at 13,000 rpm 
for 10 minutes in a benchtop microfuge with controllable temperature (Kendro). 
This was done immediately before putting the protein in an NMR tube (Wilmad-
Labglass), to produce a particulate-free sample. The cap was then placed on the 
tube and sealed with Nescofilm (Karlan) to prevent evaporation during NMR 
experiments. Typically, from 1L M9 culture of pET6H MBD2 MBD, a 600i1 
1.4mM NMR sample can be obtained. 
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2.7.1 NMR sample in 1120 
Samples in H2 0, both labelled and unlabelled, were made up to a volume of 550-
600b1l', including 10% D2 0 (Sigma). The sample also contained 10mM deuterated 
DTT and 1mM deuterated EDTA. 
2.7.2 NMR sample in D20 
A 1H sample in D20 was made by several rounds of buffer-exchange after the 
final concentration step outlined in section 2.6. The protein solution was first 
exchanged into the 99% deuterated NaPi buffer (50mM NaPi, 50mM NaCl, pH 
7.0). This was done twice so as to achieve a 500-fold dilution of any H2 0 present. 
The process of buffer exchange was repeated with 99.9% NaPi buffer,to achieve 
as high a deuteration level as possible. A description of how the deuterated NaPi 
buffer was made is given in Appendix A. 
2.8 Crystallography sample 
To make protein for crystallography, the NaPi buffer used in the gel fil-
tration step (described in section 2.5.3) was replaced with 50mM MES (2-
morpholinoethanesulphonic acid), 50mM NaCl pH 6.5. It is advisable to avoid 
phosphate buffers since these invariably crystallise, especially when combined 
with metal additives. The protein was concentrated, and the concentration of the 
sample calculated as described above (Section 2.6). 12 bp duplex DNA, with a 
symmetrically methylated central CpG pair, (sequence: 5'- G CTTAmCGTAAG C- 
'This volume in an NMR tube corresponds to the minimum depth required by the spec-












Figure 2.4: A gel filtration trace of the MBD2 MBD:DNA complex, as determined 
by absorbance at 280nm. Overlaid in different colours are successive runs of the 
same sample. Run 1, grey; 2, magenta; 3, blue. 0.5ml fractions were collected 
(not shown). 
3', Oswell), was added to the purified protein in a near-1:1 ratio. A slight excess 
of protein was maintained to reduce the likelihood of DNA-crystal formation. 
The complex was then purified by gel filtration and the trace is shown in figure 
2.4. 
A comparison of gel filtration traces shows a shorter elution time for the 
MBD:DNA complex, indicative of its larger size (see figure 2.5). The central 
peak fractions were collected and concentrated to make a stock solution of the 
complex. This was used for crystallisation trials. 
2.8.1 Crystal trials of the MBD2 MBD:DNA complex 
A sample of the MBD2 MBD:DNA complex was made as described in section 











Figure 2.5: A comparison of the gel filtration traces of free MBD2 MBD (blue) 
and the MBD2 MBD:DNA complex (red), as determined by absorbance at 280nm. 
The complex is larger, and so takes longer to elute from the Superdex 75 column. 
method, in 24-well plates. A range of buffers and precipitants make up the 
'well', while tiny drops of protein are suspended above the well, in a sealed sys-
tem. Crystals form as water diffuses out of the drop, eventually creating optimal 
growth conditions. The initial conditions were taken from previous work on 
the crystallisation of DNA binding proteins [112]. A broad-range screen yielded 
one potential candidate for optimisation. After several months at 18°C, crys-
tals were produced with 0.36mM MBD:DNA complex, in 100mM MES pH 6.5, 
and 18% 6kDa polyethylene glycol (PEG 6K). The 0.05m hexagon-shaped crystal 
was mounted in a cryo-loop and frozen in cryo-protectant (well solution plus 20% 
glycerol). In spite of attempts using both home and synchrotron (at the SRS 
Daresbury) X-ray sources, no diffraction pattern was observed. Attempts were 
made to improve crystal size and quality with additives such as divalent metal 
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Figure 2.6: SDS-PAGE gels showing the MBD protein present in selected fractions 
after the ion-exchange purification step. For MeCP2 and MBD4, the fractions 
were judged to be pure enough for SPR experiments. For MBD2, all the numbered 
fractions were pooled and further purified using a gel filtration column (see text). 
Broad range protein markers (NEB), are denoted by M, and selected molecular 
weight standards are labelled. 
cations and techniques such as microseeding, but with no success. Trials using a 
specialised broad-range DNA complex screen (Hampton Research) also failed to 
produce any single crystals. 
2.8.2 SPR samples 
Protein samples of MBD2, MeCP2 and MBD4 MBDs were made for surface 
plasmon resonance (SPR) experiments. MeCP2 and MBD4 were purified by ion-
exchange as a final step, since the level of purification required is lower. MBD2 
was further purified by size-exclusion column (see figure 2.6). Although spe-
cialised buffers were used for SPR (see Chapter 3), protein purification was car-
ried out in the buffers described above. Later on, dilution of the sample to achieve 
the required protein concentration, reduced the purification buffer concentration 
by at least 1000-fold. 
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2.9 Analysis 
Electrospray mass spectrometry [113] on the expressed MBD from MBD2 yielded 
a molecular mass of 9097 Da, which agrees well with the predicted value. There 
is no evidence that any of the MBDs dimerise, either by NMR (see section 4.5.5) 
or by analytical ultracentrifugation (AUC) [114], (data not shown). 
2.10 Sample behaviour 
The main problems encountered with the MBD2 MBD, were due to sample insta-
bility. Originally, the purified protein was known to precipitate at concentrations 
greater than 1mM, if kept below 283K for even a short time. However, at 298K 
the sample only remained in a folded state for a maximum of 4-5 weeks, during 
which time the sample quality declined (rapidly after week 3). This is not long 
enough to collect all the NMR experiments for structure determination, so mul-
tiple samples were used. The MBD as an isolated domain may lack additional 
contacts with other residues, necessary for long-term stability. 
2.11 Conclusion 
Expression levels of all constructs were excellent. In particular, the MBD2 MBD 
sample for NMR could be made from as little as 1L of culture. Expression in 
minimal media was even higher than in LB media. Problems with MBD2 MBD 
precipitation and unfolding at low and high temperatures respectively, were com-
mon. No causes have been determined for either observation, and no solutions, 
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particularly for variable sample stability were found. All experiments were there-




Previous work on investigating the affinity of different MBDs for methylated DNA 
has been done using gel shift assays [41, 115]. These were done with oligomers 
of at least 20 base pairs in length and usually with multiple methylation sites. 
In contrast, this investigation uses Surface Plasmon Resonance (SPR), a tech-
nique that allows accurate determination of equilibrium constants (gel shifts are 
non-equilibrium systems). The affinity of various MBDs for a single, central 
methylated CpG in a short oligomer, was tested. The aim was to determine 
if differences between the MBD family members are apparent in the MBD and 
methyl recognition mechanism itself. It is also possible that the proteins rely on a 
common binding mode, with other regions of the proteins responsible for specific 
binding in vivo. SPR is used to measure the affinity of MBDs from three pro-
teins for different oligomers. A comparison is made of binding to unmethylated, 




Figure 3.1: A diagram showing total internal reflection (TIR) when the angle of 
incident light is greater than 8, the critical angle. 
3.2 Surface plasmon resonance 
3.2.1 Introduction to SPR 
SPR relies on a physical phenomenon called total internal reflection (TIR) [116]. 
When light travels from a dense medium to a less-dense medium (such as when 
passing through glass to air), it is refracted at the interface of the two media. 
Some of the light is refracted and some reflected back into the denser medium, as 
shown by the blue ray in figure 3.1. However, at a certain angle of incidence, 0, 
the light is refracted so as to be parallel to the plane of the interface. This angle 
is called the critical angle, and values at, or above the critical angle produce TIR. 
In this case, no light is refracted into the less-dense medium. Figure 3.1 shows 
two angles of incidence: 01 is below, and 02 above the critical angle. So the black 
ray is an example of TIR. 
Providing the less-dense medium can absorb light at the appropriate wave- 
we 
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Figure 3.2: A diagram to illustrate how the vector component in the direction of 
the plane interface may be altered by changing the angle of incidence. 
length, the reflected beam produces an electrical field intensity, called an evanes-
cent field wave, at the media interface. If this field wave is allowed to contact a 
conducting layer, such as a gold strip, this leads to excitation and oscillation of 
the metal's free electrons. Then, electromagnetic waves called surface plasmons, 
propagate at the interface. The evanescent field wave is enhanced as the surface 
plasmons propagate on the metal, and will penetrate the less-dense medium. 
3.2.2 Resonance conditions 
Plasmons are produced in the metal layer, only when the energy and momentum 
of the incident light vector is the same as that of the surface plasmons. There 
are two ways to alter the incident light so as to arise at this situation: One is to 
change the wavelength, so changing the energy and momentum of a photon. The 
other is to change the angle of incidence so that the proportion of energy in the 
vector component parallel to the surface is altered. This is shown in figure 3.2. 
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Figure 3.3: Analyte-ligand binding alters the refractive index at the chip's surface. 
The angle of incident light required for SPR changes, and it is this change which 
is displayed in real-time in a sensorgram. Figure based on that in [117], page 26. 
As the energy of the light is transferred to plasmons, the intensity of the reflected 
light is reduced. In the case where the surfaces and wavelength are kept constant, 
a dip in the intensity of the reflected light will occur at the angle required for 
SPR. 
Although the surface plasmons are present only in the gold strip, the energy 
and momentum of their wave-vector, is affected by the density of the medium 
immediately adjacent to, (within one wavelength of) the metal strip. So small 
changes in the medium can be measured by the corresponding change in the 
angle of incidence required for SPR. This principle is exploited in BIACORE to 
measure the change in refractive index, caused by a biomolecular interaction on 
the chip's surface. In practise, rather than individual angles of 8, the BIACORE 
system uses a wedge-shaped beam of light covering a range of angles of incidence. 
A detector measures the intensity of the corresponding angles of reflection [117]. 
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3.2.3 The BIACORE system 
The BIACORE instrument brings together an optical measurement unit, remov-
able sensor chip, and automatic sample processing, all controlled by an associated 
computer. The sensor chip is made of glass coated with a thin gold layer, and 
a matrix designed for biomolecule attachment. The chip is a transducer which 
converts the change in refractive index caused by biomolecular interactions at it's 
surface into the SPR signal, which is read by the optical unit. The SPR change is 
measured in Resonance Units (RU), where 1000 RU represents a change in angle 
of 0. idegrees. This has been shown to correspond to a change in surface protein 
concentration of 1 ng/mm2. The BIACORE 2000 instrument, used in this study, 
has a detection limit of 10 RU. 
Two sensor chips were used in this study: The CM5 has a carboxymethyldex- 
trail matrix layer, and the SA chip, which has in addition, streptavidin protein 
bound to the activated dextran. Biotinylated molecules may be directly immo-
bilised on the SA chip, as biotin has an extremely high affinity for Avidin and 
Avidin-derived proteins. The CM5 chip was modified by NeutrAvidin capture 
(using the amine coupling reaction) [118], effectively converting the CM5 to a SA 
chip. 
The BIACORE system was used to measure the interaction between various 
MBD proteins and DNA oligonucleotides. The change in refractive index is mea-
sured as the analyte is allowed to flow over a sensor chip-bound ligand. Since the 
proteins are inexpensive to make, compared to purchasing DNA, these were used 
as the analyte, while the DNA was immobilised on the sensor chip via a biotin 
linker. The DNA is thus the ligand, and the MBDs the analyte, in BIACORE 
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terminology. Each chip has four flow cells, which may be handled independently 
(for instance when attaching different ligands), or together in series. The latter 
allows referencing of interactions in cells 2 to 4, with a blank cell 1. 
3.3 Experimental methods 
3.3.1 Preparation of the CM5 chip surface 
A new CM5 chip was introduced into the Biacore 2000 machine using the au-
tomated docking procedure. All four flow cells were primed with running buffer 
(50mM HEPES, 150mM NaCl, 3mM EDTA, 0.001% non-ionic surfactant P20 or 
Tween 20) and normalised by injection of 40% glycerol solution, as detailed in 
the Biacore manual [118]. To activate the dextran matrix, 60il of a 1:1 mixture 
of EDC/NHS (0.4M 1-ethyl-3- (3-dimethylaminopropyl)-carbodiimide and 0. 1M 
N-hydroxysuccinimide) was injected at a flow rate of 10[tl/min. Following this 
injection, the flow rate was increased to 50bd/min for one minute, to wash out 
any left-over EDC/NHS solution. NeutrAvidin solution (Biacore) diluted 1:6 in 
running buffer at pH 4.5 was then injected. A few microlitres were injected to test 
the response, followed by two injections of 20-30p1 solution. The total change was 
2500-3000 RU. Following 3 consecutive conditioning washes (40l 50mM NaOH, 
1M NaCl, at 40p1/min) there were no further changes in response. Individual 
flow cells were then washed with 70l 1M Ethanolamine-HC1 at 10p1/min, to 
deactivate any left-over reactive ester groups, followed by a wash with running 
buffer at 100il/min for one minute. After this stage, the CM5 chip had effec-
tively been converted to a SA chip, and the subsequent procedure was the same 
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5'-GCTTACGTAAGC-3' 	5'-GCTFAmC GTAAGC-3' 
3'-CGAATGCATrCG-5' 3'-CGAAT G mCAUCG..5' 
Unmethylated DNA (12mer) 	 Symmetrically methylated DNA 
(mel 2mer) 
5'GCTFAmCGTAAGC3' 	5'GCTTAmCGTAAGC3' 
3'-CGAAT GTATrCG-5' 3'-CGAAT GCATrCG-5' 
Methylated mismatch (T12mer). 	 Hemimethylated 12mer (hemil2mer) 
5'-GCTAmC GTAGC-3' 
3'-CGAT G mCATCG-5' 
Symmetrically methylated DNA 
(mel Omer) 
Figure 3.4: The five oligonucleot ides used as ligands in the SPR study. Methy-
lated cytosines are shown in red, the mismatched thymine in blue. Short-forms 
of the names (in brackets) are used in the text. 
for both chips. 
3.3.2 Preparation and immobilisation of oligonucleot ides 
Double-stranded oligonucleotides, biotinylated at one end, were produced by com-
bining a ratio of 1:10, 5 '-biotinylated: non-biotinylated single-stranded oligos (Os-
well). The seqences were as shown in figure 3.4. This was done to produce a 
50ig/ml stock solution (based on the biotinylated oligo concentration), which 
was heated to 45°C for 5 minutes and allowed to cool slowly. This decreased the 
likelihood of producing any double-stranded DNA molecules containing two bi-
otinylated strands. 50- to 5000-fold dilutions of the 50g/ml oligo stock solutions 
were made into running buffer. The different oligos were injected at low flow rates 
(5-10tl/min), over individual flow cells, so as to produce a change in response 
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Figure 3.5: T12mer immobilisation on a SA chip. Three injections of 50ng/ml 
T12mer are shown: 50,ul, 1001iJ, then 20il, followed by a 2 minute 2M NaC1 wash. 
The total change in response was 300 RU. 
sensorgram in figure 3.5. Following immobilisation, the oligos were distributed as 
follows: Chip 1 (a converted CM5 chip) contained 12mer, T12mer and melOmer; 
Chip 2 (CM5) contained hemil2mer; and Chip 3 (SA chip), mel2mer. 
Chip Chip type Flow cell oligomer Amount (RU) 
1 modified CM5 2 12mer 300 
1 modified CM5 3 T12mer 300 
1 modified CM5 4 melOmer 275 
2 modified CM5 3 hemil2mer 215 
3 SA 3 rnel2mer 245 
Table 3.1: Summary of transducer chips used in the SPR experiments. Each chip 
contains 4 flow cells which were handled in series during the kinetics experiments. 
The distribution of the different oligos and the amount immobilised in each case 
is shown. 
3.3.3 Preparation of proteins 
Proteins studied were the MBDs of MBD2, MBD4 and MeCP2. Sample produc-
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Figure 3.6: An overlay of the binding curves for MBD2 and mel2mer, at the full 
range of concentrations used (8uM to 2nM, in a 2-fold series). 
by a 4 minute dissociation phase. The "KINJECT" protocol, which resets the 
pumps, was used so that a continuous injection was performed. This minimises 
disturbances to the binding curves caused by mechanical noise from the instru-
ment. Regeneration conditions of 100l 2M NaCl at 100,ul/min, were required to 
re-establish the baseline after each injection. For each protein, the full range of 
dilutions was injected over each chip twice, so that the binding to all 5 oligos was 
tested in duplicate. In each of the 3 chips, a blank reference surface in cell 1 was 
used to measure the bulk contribution of the protein solutions. This response 
was then subtracted from the other cells to give the change due to protein:DNA 
interaction alone. Data are recorded in the form of a sensorgram, which displays 
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Figure 3.7: An example of curve-fitting (MBD2 and mel2mer) 
3.4 Data analysis 
3.4.1 Curve-fitting 
BlAevaluation software [118] was used for curve-fitting of kinetic data according 
to the supplied guidelines. MBD:DNA interactions are predicted to be 1:1, so 
the standard Langmuir model was used for all experiments. Simultaneous ka/kd 
fitting was carried out on a variable subset of the protein dilutions. Certain 
concentrations were excluded, either because the response curves were too low 
and below the limit of detection, or too high, with an association phase too fast 
to be fitted in relation to the rest of the series. For each data set, values are given 
for the association and disassociation rate constants, ka and kd; the equilibrium 
constants KA and KD; and the value of X2 .X 
 2  is a standard statistical measure 
of the goodness of fit, and should ideally be about the same as the noise level ( 2 
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Figure 3.8: The absence of MBD2 MBD binding to 12mer, as shown by SPR 
binding curves. 
3.5 Results 
3.5.1 Comparison of MBD binding to 12mer and 
mel2mer 
There was no detectable binding between any of the MBDs and the 12mer. Sen-
sorgrams were typically as shown for MBD2 in figure 3.8, with near-baseline 
response, even for the highest protein concentrations. This agrees well with pre-
vious work on the full-length proteins [41] and the MBD of MeCP2 [115] as seen 
by Electromobility Shift Assay (EMSA). Although preliminary studies did show a 
positive response on the sensorgram, this was always a typical "non-interaction" 
curve, as seen for MBD4 in figure 3.9 below. The completely vertical association 
and dissociation phases demonstrate the absence of an on- and off-rate. When 
these experiments were repeated, results were as for figure 3.8, and it is not clear 
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Figure 3.9: Interaction between MBD4 and 12mer 
As expected, all 3 MBDs bound to the mel2mer. The MBD of MBD2 bound 
tightly (average KD  = 350nM), but bound more weakly than the MBD of MeCP2. 
Does this reflect the ability of full-length MeCP2 to bind a single symmetri-
cally methylated CpG pair, whereas the MeCP1 complex (of which MBD2 is a 
component) prefers more densely methylated sites? It may also reflect the de-
pendence of MBD:DNA binding on elements of secondary structure outside the 
MBD. The MeCP2 construct used (amino acids 76-167) is 16 residues longer 
at the N-terminus than the MBD2 MBD. MBD4 MBD binding appears to be 
equally as tight as MeCP2, but the reported values are undoubtedly less reliable, 
due to problems with curve-fitting. In contrast to MBD2 and MeCP2, it was dif-
ficult to reproduce the fits for MBD4 and mel2mer. Values obtained from these 
experiments are shown in table 3.2 below. 
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MBD ka (M's') kd (s') KA (M-') KD (M) x2 
MBD21  8.0x104 0.023 3.5x106 2.9x10 7 0.38 
MBD22  7.3x104 0.024 3.1x106 3.2x10 7  0.28 
MeCP21 1.5x106 0.040 3.6x107  2.75x10 8  1.04 
MeCP22  1.4x106 0.045 3.1x107  3.2x10 8 0.66 
MBD41  7.6x105  0.054 1.4x107  7.2x10 8 0.87 
MBD42  2.0x106 0.066 3.0x107  3.4x10 8 0.42 
Table 3.2: Analysis of binding to mel2mer. 
3.5.2 Effect of length on methylated DNA binding 
MBD4 MBD did not bind to the melOmer, and MeCP2 MBD binding was ex-
tremely weak if present at all. A reliable analysis was not possible for these two 
proteins. Although the data-fit is relatively poor, MBD2 MBD does bind the 
shorter oligo, with a similar affinity to the rnel2mer. This is as expected from 
the structure of the MBD1 MBD in complex with a methylated 12rner DNA, 
where it was shown that DNA:protein contacts were confined to four central base 
pairs [100]. The MBDs of MBD1 and MBD2 are at least 50% identical and 70% 
similar. However, this also suggests that the DNA contact region in MeCP2 and 
MBD4 is larger than that of MBD2. This could be a feature of the subclass 
of MBDs containing MeCP2 andMBD4, which have greater similarity in their 
MBDs compared to those of MBD1-3 [41]. 
MBD (M''kd (s 1) x2
MBD21 2.4x104 








9.9x10 7  7.85 
Table 3.3: Analysis of binding to melOmer. 
3.5.3 Comparison of mel2mer, hemil2mer and T12mer 
binding 
An interaction was observed between all proteins and each of the oligos that con-
tain one or more methylated cytosines. MBD2 has the weakest MBD:DNA inter-
action, about an order of magnitude lower than those of MeCP2 and MBD4, which 
have similar KDS. MBD2 MBD has a moderate preference for the mel2mer and 
hemil2mer over the T12mer (see table 3.4), which suggests that a protein:base 
contact may be disrupted by the replacement of the amine group with oxygen. 
However, there is nothing in the MBD1 MBD:DNA structure to indicate that such 
a contact exists. MeCP2 on the other hand, moderately prefers the hemil2mer 
over the other two oligomers. 
Oligo KA (M') KD (M) 
mel2mer 3.3x106 3.1x10 7  
hemil2mer 3.1x106 3.2x10 7  
T12mer 2.3x106 4.4x10 7  
Table 3.4: Average values of equilibrium constants for MBD2 and the various 
oligos.  
Oligo KA (M') KD (M) 
mel2mer 3.4x107 3.0x10 8 
hemil2mer 7.2x107  1.4x10 8 
T12mer 3.1x107  3.3x10 8 
Table 3.5: Average values of equilibrium constants for MeCP2 and the various 
oligos. 
An average value for MBD4 and mel2mer is given, but the experiments were 
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Figure 3.10: The MBD4 and mel2mer binding curve. 
values to those for the hemil2mer and T12mer, so it's possible that MBD4 has a 
similar affinity for all 3 oligos. These results are slightly dubious however, as the 
interaction may be too fast to measure accurately at this protein concentration. 
For the T12mer, although the equilibrium constants for MBD4 and MeCP2 
are similar, MBD4 has a much faster on and off rate. A faster turnover could 
perhaps be expected due to it's function as a mismatch repair enzyme [56]. 
Oligo KA (M') KD (M) 
mel2rner 2.2x107  5.3x10 8 
hernil2rner 3.0x107  3.4x10 8 
T12rner 3.0x107  3.0x10 8 




In this study, the MBD2 MBD was found to have the weakest affinity for a 
methylated oligo. Previous attempts to quantify the MBD:DNA interaction have 
all employed non-equilibrium systems and much longer oligos, sometimes with 
multiple methylation sites. By Reverse Capillary Electrophoretic Mobiliy Shift 
Assay (R-CEMSA), mouse MBD2b was found to have a R1 /2 value of 1-8nM 
for methylated oligos (45-50 bp in length). This is compared to a value of 120-
192nM for MeCP2. Of all the MBDs tested, MBD2b was also found to have the 
greatest capacity to differentiate between methylated and unmethylated oligos 
[119]. The apparent discrepancies between the SPR and R-CEMSA data can best 
be explained by a model in which the MBD is the foundation of DNA-binding, 
but not the discriminative domain. Specificity may be conferred by regions of the 
protein outside the MBD. 
By SPR, there is no significant difference in the affinity of a particular MBD, 
for any of the methylated oligos. MBD2, however, is able to resist being com-
peted off a single mCpG, by a 100-fold excess of hemimethylated oligo, whereas 
MBD4 (and MBD1) could not [120]. This is peculiar due to the presence of mul-
tiple CpGs in the competitor - MBD2 is known to have a preference for densely 
methylated regions [41]. 
It has also been observed that by R-CEMSA, all the MBDs bind non-
specifically to unmethylated DNA [119]. In gel-retardation assays, however, the 
MBD proteins form a complex with methylated DNA, but not with an unmethy-
lated version of the same probe [120]. It is not clear if what has been observed in 
this study with an unmethylated oligo, is non-specific binding or non-interaction. 
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While preliminary studies seemed to produce a greater than 'bulk' interaction, 
these results were not reproducible. 
3.6.1 Result significance 
Estimate of error in this SPR study is given by x2  a deviation from idealised fit. 
All x2  values were comparable to the noise level and below 10% of the maximum 
response, Rrnax. The vast majority were in fact below 1% of Rmax, making 
the estimates of equilibrium constants as reliable as possible by this method. It 
was however, not possible to translate x2  into an error in nM, to allow better 
comparison of the binding constants. 
The MeCP2 construct is 20 residues longer than the MBD2 construct. This 
could have prevented it from binding the melOmer, due to steric hinderance with 
the chip matrix. The MBD4 construct is also slightly longer than MBD2, by a 
few residues, but it seems unlikely that this could have the same effect. 
3.6.2 Future investigations 
Given that there is so much conficting evidence about the affinity of the different 
MBD proteins for methylated DNA, a further SPR study would be invaluable. 
The most interesting question concerns the relative affinity of the MBD (domains) 
for DNA, compared to the full-length proteins in which they are found. Sequence 
selectivity may also play a role, as MeCP2 has been shown to prefer DNA which 
has a methylated CpG flanked by an AT rich region [50]. The sequence of the 
oligos used in this study may have resulted in increased MeCP2 affinity (see 
sequences in figure 3.4) compared with previous studies where adjacent ATs were 
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not present. An extensive study examining length, sequence and protein construct 





Nuclear Magnetic Resonance (NMR) is a technique that is mainly used to gain 
information about molecules in solution. It has become extremely useful for 
work on macromolecules due to advances in technology and understanding over 
the past 25 years. NMR exploits an intrinsic property of certain atomic nuclei, 
called spin.'. The spin state of a nucleus in an applied, external magnetic field, 
can assume one of two possible orientations. The difference between the total 
number of spins in each state (the equilibrium population difference), is the basis 
for the NMR experiment. 
NMR experiments involve applying a series of radiofrequency (RF) pulses, 
described in a pulse program, to a sample in a magnetic field. The type of pulse 
program determines what information is obtained from the sample, but in each 
case the pulses act to disturb the population difference. As the system returns 
'Only nuclei with a non-zero spin quantum number are NMR active and give NMR spectra. 
Examples include 1H, "N, 13C and 31P. 
to equilibrium, the NMR signal is recorded, which is then digitised, transformed 
and processed to generate a spectrum for analysis. 
4.1.1 Protein structure determination by NMR 
NMR spectra of macromolecules such as proteins are extremely complicated, 
due to the large number of nuclei in similar, but non-identical chemical environ-
ments. However, multidimensional heteronuclear techniques (explained below) 
resolve these signals to give information about the identity of each nucleus and 
its relative location in space. This information is used to create a list of inter-
atomic distances in a molecule, which provides an input for structure calculations. 
Bond-angle information can be included by determining through-bond coupling 
constants, and the structure may be further refined using residual dipolar cou-
plings (RDCs)2 . A computational approach is used to find possible configurations 
of atoms, which match the information collected in the NMR experiments: NMR 
is thus an indirect technique for determining protein structure. A schematic 
diagram to illustrate the process is shown in figure 4.1. 
4.2 NMR experiments 
NMR experiments were collected on Bruker Avance 800 MHz, and 600 MHz 
spectrometers, both with triple resonance (TXI) probes with triple axis gradients. 
Experiments were run using Bruker Xwinnmr 3.6 software, and standard Bruker 
pulse programs, modified by Dr. Duan Uhrmn. The different types of experiment 
2RDCs depend upon the relative orientation of bond vectors with respect to a common axis. 
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Figure 4.1: A schematic diagram to illustrate the process of protein structure de-
termination by NMR. Each stage is described more fully in this and the following 
chapter. 
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and their use, are outlined below. 
4.2.1 Homonuclear experiments 
The most useful, and fortunately also the most abundant, nucleus in protein 
NMR is the proton ('H). Homonuclear experiments collect information from pro-
tons only, but this is not as limited as it might seem. Protons are affected by their 
local chemical environment which is apparent by a specific shift of their position 
in the NMR spectrum. Chemical shifts arise due to local variations in the mag-
netic field experienced by an individual nucleus. In general, a nucleus is shielded 
against the effects of the external magnetic field by its orbiting electrons, and is 
deshielded if those same electrons are drawn away (for example by an electroneg-
ative neighbouring atom). Shielding corresponds to a decrease, and deshielding 
to an increase in the frequency at which a particular nucleus resonates. 
Sidechain CH3 
Trp indole 	Aromatic ring & 
HN sidechain HN 	Sidechain CH, CH2 
4 	 4 	 4 
1H1' 	10 	9 	8 	7 	6 	
5 	4 	3 	2 	1 	0 	-1 
P.P.M. 
Figure 4.2: A 1D proton spectrum of an unlabelled sample of the MBD2 MBD. 
Regions of the spectrum are labelled to show where particular chemical types are 
found. 
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4.2.2 1D 'H experiment 
The one dimensional 111  experiment produces a spectrum displaying the relative 
frequency, expressed in parts per million (p.p.m.), of every proton in the sample. 
Although there is a large variation in the local chemical environment experienced 
by each proton, particular chemical types are found in certain areas of the spec-
trum (see figure 4.2). This spectrum is very overlapped and cannot be used for 
resonance assignment, since there is no way of identfying individual atoms. How-
ever, it is useful for examining the general quality of the sample, as small-molecule 
contaminants and protein unfolding can be detected by a 1D experiment. 
4.2.3 Multidimensional experiments 
Due to the complexity of 1D protein NMR spectra, it is necessary to spread signals 
out over two or more dimensions. In a multidimensional experiment, magneti-
sation is transferred between nuclei at the end of an evolution time of variable 
length. The resulting spectrum is a function of multiple frequency variables, and 
gives information about nuclei that are coupled, either through bonds (scalar, or 
J-coupling) or through space (dipolar coupling). Heteronuclei (nuclei other than 
111) can also be studied in these experiments. This is discussed in section 4.2.5. 
4.2.4 2D homonuclear experiments 
Several different types of 2D homonuclear experiment were used in this project, 
and an overlay of two experiments is shown in figure 4.3. In a 2D correlated 
spectroscopy (COSY) experiment, magnetisation is transferred between protons 
that are no more than three bonds apart. On-diagonal peaks represent magneti- 
sation which has not transferred to a second nucleus, whereas so-called crosspeaks 
appear at the chemical shifts of paired nuclei. COSY crosspeaks are useful for 
identifying aromatic ring protons and protons in longer sidechains. The total 
correlated spectroscopy (TOCSY) experiment is similar to COSY, except that 
the scalar coupling is not limited to three bonds, but may correlate all protons 
in a spin-system. An example of a spin system is a single amino acid residue, 
although overlap often prevents assignment of all the atoms. This is a particular 
problem with HS and He, in lysine and arginine sidechains 
The NOE spectroscopy (NOESY) experiment correlates all protons within a 
certain distance of each other. This is possible due to the nuclear Overhauser 
effect (NOE). The mixing-time must be carefully chosen to allow long enough for 
magnetisation transfer to take place whilst still retaining signal intensity, before 
it decays due to spin diffusion3.The size of an NOE crosspeak is approximately 
inversely proportional to the sixth power of the distance between the nuclei. 
Therefore, NOESY crosspeaks are useful for both identifying individual atoms, 
and determining their relative location in space. This property forms the basis 
of structure determination by NMR. 
In this project, 2D homonuclear experiments were run in D20 to prevent 
a strong water signal obscuring part of the spectrum. The Hc. region (3.5 - 6 
p.p.m.) is particularly vulnerable to this effect, due to water protons resonating 
at around 4.8 p.p.m. The problem with samples in D20, is that labile protons 
undergo chemical exchange with the solvent, and so become invisible in a 111 
experiment. Fortunately, the purpose of these experiments is to identify stable 
3A leakage of magnetisation to surrounding nuclei 
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Figure 4.3: An overlay of 2D homonucear spectra of the MBD2 MBD in D20, 
at 288K. Positive and negative contours are shown in black and red (NOESY), 
and blue and green (TOCSY) respectively. Both axes display 'H shifts in p.p.m. 
aliphatic and aromatic, rather than amide protons, for which other experiments 
are used. 
4.2.5 Multidimensional heteronuclear experiments 
In protein NMR, 'H is not the only magnetically active nucleus. The heteronuclei 
'5N and 13C can be used, although they have a low natural abundance. This 
means that samples have to be isotopically enriched for one or both isotopes 
(see Chapter 2). They also have much smaller gyromagnetic ratios than 'H, 
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which results in low detection sensitivity'. This latter problem is minimised by 
having heteronuclei as intermediates in the magnetisation transfer process, while 
'H remains the nucleus from which magnetisation originates and on which signal 
detection takes place. 
4.2.6 The HSQC experiment 
A very important 2D experiment is the heteronuclear single quantum correlation 
(HSQC) experiment. In the 15N-HSQC, nitrogen atoms are correlated with their 
directly attached protons (if they have them). Each HSQC peak corresponds to 
one incidence of an NH, which are predominantly found in the protein backbone. 
Side-chain NHs, found in arginine, histidine and tryptophan, and NH2 groups of 
arginine, asparagine snd glutamine may also be seen. There is no diagonal in an 
HSQC spectrum, as different nucleus types with very different frequency ranges, 
are observed and correlated. A similar experiment, the '3C-HSQC, correlates all 
carbon-attached protons with their corresponding carbon atom. 
4.2.7 3D 15N experiments 
3D '5N experiments are a combination of a 2D homonuclear experiment and the 
'5N HSQC. The purpose is to resolve signals that were overlapped in the 2D 
experiment, by correlating them with a third heteronuclear dimension. In the 
TOCSY version, scalar couplings, from an NH to protons in the same residue are 
observed. The '5N NOESY is used to correlate NH with all the protons close 
in space. Together, these experiments allow sequential assignment of the protein 
'The NMR frequency, ii, of a nucleus in a fixed magnetic field, is directly proportional to its 
gyromagnetic ratio, y. 
71 
sequence (described in section 4.5.2), and the NOESY is also used to derive inter-
atomic distances (see Chapter 5). A schematic diagram of the 3D experiment is 








15N (or 13C) 
Figure 4.4: A schematic representation of 3D experiments with an HSQC step. 
The 15N HSQC face of the cube is shown in grey, and a 'H-'H slice with four 
crosspeaks (in white) is indicated. The slice is through a 15N HSQC peak and so 
is called a 15 N plane of the experiment. 15N planes are used to identify amino 
acid types (from the shifts of the sidechain nuclei) and establish sequential con-
nectivities. '3C can also be used as the third resolving dimension, for instance in 
the HCCH-TOCSY experiment (see section 4.2.8). 
4.2.8 HCCH-TOCSY and 13C NOESY 
In the HCCH-TOCSY experiment, magnetisation is first transferred from a pro-
ton to its directly attached carbon. This is followed by a fast TOCSY transfer to 
neighbouring carbons, and finally to their directly attached protons, from which 
detection takes place. It is an extremely useful experiment, since every 1H-'3C 
pair is correlated with every other proton (and hence its attached carbon), in the 
same residue. A complete assignment of each spin system can be achieved by 
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Figure 4.5: Magnetisation pathways of three triple resonance experiments, which 
give rise to the experiment names. 
comparing crosspeaks in related '3C planes. This information cannot, however, 
be directly linked to the corresponding backbone amide shift, since the experi-
ment lacks a '5N dimension. Instead, by working out likely residue types from 
crosspeak patterns, and by comparing chemical shift values obtained in other ex-
periments, each spin system is assigned to a particular residue. The 13C NOESY 
is analogous to the HCCH-TOCSY experiment, except that the correlations are 
not limited to through-bond couplings. The spectrum strip belonging to each 
'H-13  C pair will contain a NOESY crosspeak for every dipolar coupled proton. 
4.2.9 Triple resonance experiments 
Triple resonance experiments are used for identifying sidechain 13C shifts, cor-
relating these with backbone amide shifts and thus sequentially assigning the 
protein chain. Each of the experiments is named after the magnetisation path-
way it employs to probe the protein molecule; undetected nuclei are shown in 
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Experiment Solvent Mixing time Processing T (K) Ref. 
2D '5N HSQC H20 - FT 288 [122] [123] 
2D 13C HSQC H20 - FT 288  
2D 'H NOESY D20 100 ms FT 288  
2D 'H TOCSY D20 60 ms FT 288 [125] 
2D 1H COSY D20 - FT 288 [125] 
3D '5N NOESY H20 100 ms MEM 288 [123] 
3D HCCH-TOCSY H20 15 ms MEM 288  
3D '3C NOESY H20 100 ms MEM 288  
3D CBCA(CO)NH H20 - MEM 298 [130] 
3D HNCACB H20 - MEM 298 [129] [131] 
3D CC(CO)NH H20 - MEM 298 [132][133] 
3D '5N NOESY H20 100 ms MEM 298 [126][123] 
3D 15N TOCSY H20 35 & 60 ms MEM 298 [123] 
Table 4.1: A summary of experiments collected on the MBD2 MBD. Solvent 
described as H2 0 is actually 90% H20, 10% D20; T is temperature in Kelvin. 
For a general introduction to the various NMR experiments, see [125]. 
brackets. The CBCA(CO)NH experiment correlates each NH with the C and 
C,9 carbons of the previous residue. HNCACB, an out-and-back experiment, cor-
relates each NH with Ca  and C,3  from both its own spin system and that of the 
preceding residue. CC(CO)NH is designed to correlate NH with the Ca  and all 
other 13C sidechain resonances of the previous residue. The magnetisation path-
ways are shown in figure 4.5. A description of how these experiments were used 
for sequential assignment is given in section 4.5.2. 
4.3 Data acquisition 
In one model of NMR, magnetisation is described as a vector, rotating about the 
field direction (Z axis) at an angular velocity proportional to the field strength. 
In an NMR experiment, the total field is not stationary and also rotates about 
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Figure 4.6: Detection of the NMR signal. A:The magnetisation induces a decay-
ing sine wave in the receiver coil. B:Quadrature detection allows the sign of the 
frequency to be determined, by summing frequency-domain data from orthogonal 
axes. 
to be stationary, we can more easily visualise the behaviour of the magnetisation 
vector'. At the end of an NMR experiment, the magnetisation components, are 
flipped into the XY plane where they induce a current in the receiver coil, located 
on the X-axis. This gives rise to a decaying sine wave, called a free induction 
decay (FID), the NMR signal. The sine wave is a result of plotting the current 
induced in the coil as a function of time, and it decays as the spins gradually 
dephase (due to relaxation). 
In reality, it is not possible to detect the direction of rotation of the vector 
using only one receiver. This is because there are two possible Fourier transforms 
of the sine wave. A second detector for the imaginary component, allows positive 
and negative vector rotation to be distinguished, by summing real and imaginary 
components. This is known as quadrature detection. Since the transmitter fre-
quency can then be placed at the centre of the spectrum, and the digital filters 
'Magnetisation is thus observed in the rotating-frame of reference. 
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set to a narrower range, less noise is folded back into the spectrum, improving 
the signal-to-noise ratio (SNR). 
4.3.1 Data improvement by FID manipulation 
Due to experimental time limitations, a number of processes are used to gain 
maximum quality and resolution from data that are otherwise limited. 
Zero-filling is the process of increasing the digital resolution of a spectrum by 
adding null data to the FID. Resolution is proportional to the density of sampling 
the data and the interval between sample points is inversely proportional to the 
acquisition time. So, by artificially increasing the size of the data array, enhanced 
digital resolution is possible without increasing the acquisition time (or decreasing 
the sweepwidth). This is only valid if the FID does actually decay to zero, and 
in reality there isn't time to wait until this eventually happens. Instead, the FID 
is multiplied by a window function to cause the FID to decay smoothly to zero 
- this is called apodisation. There are different types of window function, which 
apply a weighting to different parts of the FID. Gaussian and sinebell squared 
are common functions, which serve to improve resolution and maintain a good 
signal-to-noise ratio (SNR), without introducing excessive line-broadening. 
4.4 Data processing 
4.4.1 Processing methods 
The FID is a composite of many signals, of varying amplitude and frequency. 
The individual signals may be extracted from the FID using several methods, 
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sinebe112 	 gaussian 
Figure 4.7: Examples of window functions used in this project. The FID is 
multiplied by a window function before Fourier Transformation, in order to make 
the signal decay smoothly to zero. Zero-filling may then be used to improve the 
digital resolution of the spectrum. 
two of which were used in this project. Fourier Transformation (FT) converts the 
time-domain FID to a freqency-domain spectrum with both real and imaginary 
components. Subsequent phasing of the data reduces the contribution of the 
imaginary part, so that only the real (pure absorption Lorentzian) lines are seen 
in the spectrum. The Maximum Entropy Method (MEM) works by reconstructing 
FIDs from simulated frequency domain spectra, by inverse FT. Because there are 
numerous spectra which could be transformed in this way to generate the same 
FID, the method selects the simplest solution, that with the maximum entropy. 
4.4.2 FT processing 
The AZARA suite of programs [134] was used for all NMR data processing. A 
script used to process a 2D experiment (a '5N HSQC), by the FT method, is 
shown in Appendix B. First, the directly detected ('H) dimension was processed 
(with the program process), and the 1D spectrum of the first transient plane 
was viewed with plot2. After appropriate phase correction, the second (15N) 
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dimension is processed and the resulting 2D spectrum viewed. After further 
phase and baseline corrections, the spectrum is referenced and an appropriate 
contour threshold level selected. 
4.4.3 Maximum entropy method processing 
All 3D experiments in this project were processed with the MEM in the indi-
rectly detected dimensions. This is advantageous since the digital resolution in 
indirect dimensions is often limited by the time available for data acquisition. 
Data are first processed by the FT method, then commands for MEM processing 
are added into the script for the relevant dimensions (see example in Appendix 
B). Spectral noise is estimated by analysis of 2D planes of each dimension, using 
plot2. Individual planes are processed and the result compared with FT pro-
cessed data. The aim is to improve the resolution of the spectrum, without loss 
of information. Processing the whole spectrum with MEM is very computation-
ally intensive, which is why it is first optimised on a number of 2D planes. After 
processing the entire spectrum, the log files are checked, to see if all the 2D planes 
have converged. A program written to do this is shown in Appendix B. MEM 
processing often completely failed on planes dominated by water signal. 
4.4.4 Contour generation and display 
The AZARA [134] program contours is used to generate contour levels, both 
positive and negative starting from the contour threshold level used in plot2. A 
contours input script is shown in Appendix B. The output is read, along with the 
experimental parameter file, by ANSIG, an assignment program [135]. ANSIG 
allows easy navigation of multiple spectra, keeps track of assignments, and has 
a number of associated macros. These simplify the assignment process, and 
subsequent data manipulations such as crosspeak integration. 
4.5 Assignment 
4.5.1 Overview of assignment strategy 
The experiments described in the previous section, were used to carry out the 
process of assignment. This involves assigning each particular resonance within 
the spectra, to a particular atom in the molecule. Firstly, in protein NMR, a 
limited set of (mainly backbone) assignments are used to determine sequential 
connectivity. Next, all remaining atoms in the simpler sidechains are assigned. 
Finally, aromatics and longer sidechains are assigned. Once all the assignments 
have been made, these are used to assign NOESY crosspeaks, which represent 
through-space connections. From these, distance restraints are derived for struc-
ture calculation. 
4.5.2 Sequential assignment 
Sequential connectivities may be determined using either 3D '5N data, '3C data 
or both. Starting from a 15N HSQC crosspeak, the corresponding '5N plane of 
the 3D data (see figure 4.4) is examined. A '5N-1H-'H TOCSY experiment pro-
vides information about atoms within a residue, and the corresponding NOESY 
experiment about atoms that are close in space, including inter-residue proxim-
ities. Therefore, NOESY crosspeaks matching those in the TOCSY experiment, 
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Figure 4.8: Three '5N slices of 15N-NOESY (black and red) and 15N-TOCSY 
(blue and green) spectra, showing how the data are used for sequential assign-
ment. Some assignments shown were only determined in conjunction with other 
experiments. 
will be present in the '5N plane of the next residue. This procedure may also be 
done in reverse: by searching for NOESY-matching TOCSY crosspeaks, in the 
'5N plane belonging to the previous residue. Thus it is possible to string together 
the amino acid chain (see figure 4.8), until a proline is reached or the informa-
tion is limited. Proline inevitably breaks up this linking process as it lacks an 
NH. Matching peaks may also be found in a number of different '5N planes, so 
connections must be worked out by a process of elimination. For MBD2 residues 
F:" 
172, 186 and 207-215, no proton chemical shift information was obtained using 
the 3D 15N experiments. 
To complement the procedure described above, it is possible to use a similar 
principle to sequentially assign a protein chain using 13C resonances (see figure 
4.9). The experiments required are CBCA(CO)NH and HNCACB (see figure 4.5 
and earlier description). CBCA(CO)NH relates the NH resonance of residue i, 
to the Ca and CO of residue i-i. HNCACB correlates Ca and CO to NH of 
the same residue, i. Sequential residues in the chain can therefore be connected 
by finding CBCA(CO)NH crosspeaks that match HNCACB peaks at another NH 
resonance, and vice-versa. Ca and /3 crosspeaks in the HNCACB experiment have 
the opposite sign to each other, so this identifies which shift is which. In both 
cases, comparison of 'H and '3C shifts with a database of average chemical shifts, 
and information from the CC(CO)NH experiment, give clues to the identity of 
the residue. Although several residues have similar patterns of crosspeaks (eg. 
aromatic residues), chains of linked residues may be identified by comparison with 
the amino acid sequence. 
4.5.3 Side-chain assignment 
Carbon side-chain assignments, other than Ca and CO are initially obtained from 
the CCCONH experiment, whilst some proton resonances are found in the 3D 
15NNOESY and -TOCSY experiments. Detailed, systematic assignment how-
ever, is obtained by analysis of the HCCH-TOCSY experiment. This correlates 
all carbon-attached protons within a residue, and each C-H connection is tracked 
using a '3C HSQC (or a 2D, '3C-1H, projection of the '3C NOESY). As well as 
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Figure 4.9: Two '5N slices of triple resonance spectra, showing how the data 
are used for sequential assignment of the protein chain. CBCA(CO)NH contours 
are shown in blue (positive) and green (negative, folded), whilst HNCACB con-
tours are in black and red respectively. Some slices (such as the F190) are easy 
to interpret, whilst K189 has an NH resonance in an overlapped region of the 
spectrum. 
identifying previously unassigned atoms, the HCCH-TOCSY experiment discrim-
inates between protons attached to the same carbon atom, and those attached 
to different carbons; a detail not found in '5N experiments. Other experiments 
used to cross-check assignments are homonuclear NOESY, TOCSY and COSY 
experiments in D20. These are useful, particularly for identifying aromatic proton 




The first set of experiments collected on the MBD2 MBD were done at 298K, 
whilst subsequently it was discovered that the stability of the protein improved at 
288K (see Chapter 2). Although all experiments to provide restraints for struc-
ture calculation were obtained at the same temperature (288K), some assignment 
experiments were carried out at 298K. The temperature difference of 10K caused 
a variable change in the chemical shifts found in backbone assignment experi-
ments ('3C experiments and one set of 15N experiments). Proton shifts are more 
sensitive to local environment changes induced by temperature, due to the effect 
on H-bonding and water exchange rates. This problem was resolved by transfer-
ing proton assignments from a 15N NOESY at 298K, to a 15N NOESY experiment 
at 288K. 
4.5.4 NOESY assignment 
NOESY experiments help to establish sequential connectivities, identify residues 
and determine proline isomer types. Once the assignment process was completed, 
additional crosspeaks, corresponding to through-space connections, were picked in 
the '3C- and 15N-NOESY experiments. This was done by carefully considering all 
possible contributions to a particular crosspeak. For each possible contribution, 
the symmetry-related peak (in another spectrum, or another part of the same 
spectrum) was sought. If more than one pair of atoms could be contributing to 
the crosspeak, or there was any doubt about the authenticity of the assignment, 
the crosspeak was left unassigned. Such crosspeaks are "ambiguous" and are 
handled in a different way to crosspeaks whose assignment is unambiguous. It 
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Figure 4.10: A summary of the assignment of the MBD2 MBD at 288K. Each NH 
crosspeak is labelled with the single letter amino acid code and sequence number. 
Positive contours are shown in black, negative in red. 
is crucial to be careful about assignment of NOESY crosspeaks as mistakes will 
bias the structure calculation. This is explained in more detail in Chapter 5. 
4.5.5 Summary of MBD assignment 
Assignment of the free MBD at 288K was carried out using the experiments 
summarised in table 4.1, and is 86% complete (excluding the His tag). An as-
signed '5N HSQC is shown in figure 4.10 and the full chemical shift list is found 
in Appendix C. These data were used for structure determination, as described 
in Chapter 5. The MBD2 MBD appears to be monomeric in solution, as the 
number of peaks in the '5N HSQC correspond approximately to the number of 
amino acid residues. The possibility of a perfectly symmetrical homodimer can 
be excluded, as there is insufficient line-broadening in the spectrum associated 
with the slower tumbling of a larger molecule. There is evidence for minor forms 
of some amino acids however, most likely caused by proline isomerisation leading 
to localised chemical shift changes. As the peaks were generally very weak, there 
was insufficient data to link alternative amino acids forms and so include them 
in the assignment. For some residues, the alternate form predominated at 298K 
making transferring of assignments and comparison with the complex difficult. 
4.6 	Studies of the MBD:DNA complex 
Although NMR and crystallographic techniques were employed to investigate the 
interaction between the MBD and methylated DNA, attempts to crystallise the 
MBD:DNA complex were unsuccessful (see Chapter 2). NMR is thus the sole 
method used in this project to probe the structure of the MBD. 
4.6.1 MBD:DNA complex preparation for NMR 
A '5N, '3C-labelled protein sample was titrated with a 12 bp, symmetrical DNA 
duplex, with a methylated central CpG pair (sequence: 5'-GCTTAmCGTAAGC-
3', Oswell). High quality, purified and dried DNA oligomer was made up to a 
concentration of 1mM, with dH20. Ten aliquots of 200i1 were lyophilised ready 
for titration into the MBD sample. '5N HSQC spectra were used to monitor the 
titration. After each spectrum was collected, the sample was removed from the 
magnet and carefully pipetted into an eppendorf with lyophilised oligomer. In 
this way, each titration step increased the DNA concentration by 0.2mM. After 
mixing the protein sample with a new aliquot of DNA, the tube was centrifuged 
for 5 minutes at 13,000rpm and then replaced back into the NMR tube. The sam-
ple was put back in the magnet, re-locked and shimmed before the next HSQC 
spectrum was recorded. All parameters were kept identical so that changes due 
to the increased DNA concentration could be clearly observed. In particular, the 
receiver gain was set at a lower than optimal level and the temperature moni-
tored. Each time, the sample was allowed at least 15 minutes to equilibrate at 
temperature, inside the magnet. An intermediate exchange regime was expected, 
due to previous experience with the MBD:DNA complexes of other proteins [136]. 
Since the frequency difference (in Hz) between two states depends on the field 
strength, the titration was carried out at 600MHz rather than 800MHz. This 
increases the likelihood of observing faster exchange, and thus being able to see 
peaks of the MBD:DNA complex, in the '5N-HSQC spectrum. The titration was 
continued as long as changes in the HSQC spectrum were observed. Figures 4.11 
and 4.12 show the HSQC spectra of the titration. 
4.6.2 Effect of DNA titration 
In the early stages of the DNA titration, almost all the 15N HSQC peaks disap-
pear. After the addition of five aliquots (1mM DNA), all that remains are peaks 
from extreme C-terminal residues and the amino ends of Gln and Asn sidechains. 
This indicates that the system is in intermediate exchange. The signals in the 
HSQC are extremely broad, due to a coalescence of the two resonance states 
resulting from complexed and free protein. The protein is in excess, with a con- 
centration in the range 1.4-1.6mM, as calculated during the purification process. 
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Figure 4.11: Titration of the MBD2 MBD with double-stranded, methylated 
DNA (sequence: 5'-GCTTAmCGTAAGC-3'), monitored using the '5N HSQC 
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Figure 4.12: .Titration of the MBD2 MBD with double-stranded, methylated 
DNA (sequence: 5'-GCTTAmCGTAAGC-3'), monitored using the '5N HSQC 
experiment. Part II. 
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Adding more DNA to the sample, restored many of the peaks to new positions 
in the spectrum. The complexed form of the protein has become the dominant 
resonance state. Although the spectrum is poor, and the peaks are weak due to 
exchange broadening, it is possible to see that some dramatic shifts have taken 
place. During the titration process, no further change was observed after adding 
the final aliquot of DNA (2mM). Later inspection of the spectra revealed that 
the receiver gain had been set too high for the experiment at 1.8mM DNA. There 
is in fact little difference between 1.6mM and 1.8mM. A slight excess of DNA is 
therefore present in the final sample. 
4.6.3 Changing the temperature 
In spite of having an at, or near equimolar MBD:DNA ratio, the HSQC spectrum 
of the complex is still very poor and intermediate exchange is still in evidence. 
The type of exchange regime in NMR depends on the size of the exchange rate 




Equation 4.1 describes the relationship between the exchange rate, k and the 
frequency difference (5v) in intermediate exchange. If k is greater than the right 
hand side of equation 4.1, the system will be in fast exchange. 
To alter the exchange regime from intermediate towards fast, the temperature 
was increased in four steps from 288K to 298K. Figure 4.13 shows the effect this 
had on the HSQC spectrum. The quality of the spectrum improves steadily, until 
at 298K, a good spectrum of the complex is obtained. The spectrum is better 
dispersed than that of the free protein, which indicates a more structured protein 
backbone in the complex. 
4.6.4 Sequential assignment of complex 
In order to assign the '5N HSQC of the MBD:DNA complex, '3C backbone ex-
periments, CBCA(C0)NH and HNCACB, described previously, were collected 
at 298K on a 600MHz spectrometer. From this pair of experiments, sequential 
assignment was completed, with 80% of Ca and CO atoms assigned. This process 
was made easier by knowledge gained from the assignment of the free protein. 
The improved quality of the connections in the backbone assignment suggested 
that the whole molecule had become more rigid in the complex. The C-terminus 
was much more ordered, but backbone amide assignments for residues 210-213, 
could still not be found (see figure 4.14).A summary of experiments collected on 
the MBD:DNA complex, is shown in table 4.2. 
Experiment Solvent Processing T (K) Ref. 
2D '5N HSQC 1120 FT 288-298 [122] [123] 
31) CBCA(C0)NH 1120 MEM 298 [129] [130] 
3D HNCACB H20 MEM 298 [129][131] 
Table 4.2: A summary of experiments collected on the MBD2 MBD in complex 
with methylated DNA. Solvent described as H2 0 is actually 90% H20. 15N HSQCs 
were collected at a range of temperatures; T is temperature in Kelvin. 
4.6.5 Assignment of the MBD at 298K 
In order for a comparison to be made between the free and bound states of the 
MBD, a limited assignment of the free protein at 298K was carried out. This 
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Figure 4.13: Effect of changing temperature on the '5N HSQC of the MBD2 
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Figure 4.14: A summary of the assignment of the MBD2 MBD:DNA complex at 
298K. Each NH crosspeak is labelled with the single letter amino acid code and 
sequence number. Positive contours are shown in blue, negative (folded) in green. 
was done using a combination of the backbone experiments collected at 298K 
(see table 4.1) and information from the completed assignment at 288K. It was 
possible to assign the '5 N-HSQC, apart from a few residues in the disordered 
termini (150-151, 210, and 213-215) and Lys170. This residue is only observed at 
298K, in the bound state. Figure 4.15 shows the assigned spectrum. 
4.6.6 Comparison of NH chemical shifts 
Using data of the free MBD collected at 298K, it was possible to compare chemical 
shifts of free and DNA-bound protein. A graph of backbone amide chemical 
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Figure 4.15: A summary of the assignment of the MBD2 MBD at 298K. Positive 
contours are shown in green, negative (folded) in orange. Each NH crosspeak 
is labelled with the single letter amino acid code and sequence number. These 
assignments were used for comparing chemical shift changes induced upon DNA 
binding. 
shift changes induced upon DNA binding is shown in figure 4.16, part A for 
MBD1 MBD, and figure 4.16, part B for MBD2. A similar pattern of changes 
is seen for both proteins, and they also compare well with data for the MBD 
from MeCP2 [98]. The most affected residues are in the loop, Li, and the a-
helix plus the preceding loop. In MBD2, large chemical shift changes are also 
likely to occur in the C-terminal region corresponding to the hairpin loop in 
MBD1, but are not seen due to incomplete assignment of these residues. In 
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Figure 4.16: A:Graph to show chemical shift perturbation upon DNA binding to 
the MBD of MBD1. '5N shifts are in the lower panel and 'H shifts in the upper 
panel. Taken from [99] with the authors' permission. B:Graph to show chemical 
shift perturbation upon DNA binding to the MBD of MBD2. Stacked shifts are 
shown. '5N shifts are in maroon and 'H shifts, scaled up by a factor of five, are in 
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Figure 4.17: Graph to show chemical shift perturbation upon DNA binding to 
the MBD of MBD4. Stacked shifts are shown. '5N shifts are in maroon and 'H 
shifts, scaled up by a factor of five, are in blue. 
DNA-binding interface [100]. Smaller changes were observed on MBD1 MBD 
binding to an identical but unmethylated probe, and the system exhibited a fast 
exchange regime. The equivalent experiment was not done with MBD2, but in 
surface plasmon resonance studies, for all MBDs tested, binding to unmethylated 
DNA could not be detected (see Chapter 3). 
MBD4 NH shift changes 
A similar titration was done with the MBD from MBD4, and a single-stranded, 
8-mer, hairpin oligonucleotide (sequence: 5'- GAGmC GTCT-hexaethylene glycol-
AGATGCTC-3', Oswell). The construct used was the same one described in 
Chapter 2 (see table 2.1) except the N-terminal tag had been cleaved off leaving 
only residues 61-141 and three, non-native residues (AMA) at the N-terminus. 
This work was done by Brian Smith. The backbone amide chemical shift changes 
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are shown in figure 4.17 for comparison. Although the same general trend is 
observed as for the other MBDs, some missing assignments make the pattern less 
obvious. The largest changes are observed around residues 84 and 92, which are 
at the beginning and end of the Li loop equivalent region. The middle of this 
loop showed the greatest change in MBD1 and MBD2, but Gly87 is unassigned 
in MBD4, making a comparison impossible. The completely conserved region 
around Phe105 also showed a large change in chemical shift upon DNA binding. 
The equivalent residue to Arg106, (Arg44 in MBD1) forms a major groove contact 
from the base of the cr-helix. It is also one of five residues which make up the 
hydrophobic, methyl-recognition patch [100]. Residues 124-127 are an insert, 
present in MBD4 and MeCP2, but not in the other family members. There is 
no evidence for any role in DNA binding for these residues, as their resonance 
positions are unchanged. 
4.6.7 13C shifts 
A difference in backbone carbon shifts, may indicate a change in the basic sec-
ondary structure [137]. For MBD2, Ca shifts remain virtually the same in all 
but a few residues. Shifts above 0.5 p.p.m. are only observed for 7 residues in 
the Li equivalent region, and for Arg191. This is consistent with the model of 
DNA-binding in which only a small part of the MBD changes shape. The pattern 
for C/3 shifts indicates that residues 170-181 and 191-192, are the most affected 
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Figure 4.18: Graph to show Ca and C/El chemical shift perturbation upon DNA 
binding to the MBD of MBD2. Contributions from each resonance are stacked, 
coloured and labelled accordingly. Incomplete assignment of spectra made com-
parison of some residues impossible (shown as zero). 
4.6.8 X-filtered experiments 
X-filtered experiments for measuring inter-molecular NOEs [138], were collected 
on the sample of the MBD:DNA complex, but none were observed. It is not clear 
why this was the case, as 91 intermolecular NOEs were identified in the structure 
of the MBD1:DNA complex [100]. 
4.7 Chapter conclusion 
At 288K, sufficient NMR experiments were collected to enable 86% of native 
MBD2 MBD atoms to be assigned. The '5N-HSQC of the free protein is of 
reasonable quality and most residues were easily identified using either '5N-, or 
'3C-backbone experiments. The data suggested a typical MBD fold, with struc- 
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tured regions of the correct length matching /3-sheets, interspersed with less well-
ordered loops. Residues 194-201 had strong Ha-NH crosspeaks both within a 
residue and between residues 3-4 apart, consistent with an c-helical structure. 
The C-terminus is the most disordered region, but this is due to its flexibility, 
shown by broadened '5N line widths (see particularly residues 207S, 209F, 211F 
and 216M in figure 4.10). Proline isomerisation is likely to be responsible for 
alternate, minor forms of some residues, although only the major form could be 
assigned and sequentially linked. For instance, A1a157 and Leu158 in the se-
quence PALP, are very weak but identifiable. Assignments of the MBD2 MBD 
were used for structure determination of the free protein, described in Chapter 5. 
Titration of the MBD2 MBD with a methylated duplex DNA produced a 
complex in an intermediate exchange regime. Increasing the temperature by 
10K, to 298K, vastly improved the quality of the HSQC spectrum. It was then 
possible to collect backbone experiments and complete a backbone assignment of 
the MBD:DNA complex. A similar procedure had previously been carried out on 
the MBD4 MBD. From NMR studies of the complexes, a mode of DNA binding 
very similar to that of the MBD1 MBD is expected for both MBDs. The DNA-
binding surface appears to be well conserved, and the domain does not undergo 
major structural changes on DNA binding, in either MBD2 or MBD4. The only 
exception is the Li loop region and a residue immediately preceding the a-helix, 
R191 (11106 and neighbouring residues in MBD4). Few conclusions can be drawn 
about the function of the C-terminal hairpin loop due to incomplete data for 
MBD2, but it appears to be inflexible in MBD4. Figure 4.19 maps the largest 
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Figure 4.19: The largest shift changes induced upon DNA binding are labelled. 
The five hydrophobic patch residues, reportedly responsible for methyl-specificity 
are boxed in red. Each NH crosspeak is labelled with the single letter amino acid 
code and sequence number. Contours of the complex are coloured blue (positive) 






This chapter describes how the information obtained from NMR experiments 
(explained in Chapter 4) was used to determine the structure of the MBD from 
MBD2. The final, calculated structure is discussed and compared to that of other 
MBDs. 
5.2 Distance restraint generation 
The applications of the NOE experiment have been described previously (see 
Chapter 4). In short, the intensity of the NOE between two nuclei is inversely 
related to the sixth power of the distance between them. Using ANSIG [135], the 
NOE crosspeaks in both NOESY experiments were integrated to give a measure 
of their intensity. This information was then compiled in a list, containing the 
chemical shifts, assignments and relative intensities of all marked (ie. recognised, 
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but not necessarily assigned) peaks. The crosspeak file was then subjected to a 
number of manipulations in order to extract and sort this information. There 
are several objectives of this sorting process. The first is to select nuclei with 
an unacceptably high chemical shift range (e.g. >0.05 p.p.m. in 'H) and check 
the relevant assignments and peak positioning in ANSIG. There were very few 
of these so-called "offenders" in this project. All were eliminated after a single 
re-examination of the spectra. Secondly, a table of connected nuclei was created. 
This summarises chemical shift information for protons, together with that for 
their attached heavy atoms. Finally, the table of connected nuclei described 
above, was correlated with the list of NOESY crosspeaks, from both '5N and 
'3C spectra. This was done separately for each spectrum, thus producing two 
files of crosspeaks with their matching assignments. Some crosspeaks match the 
chemical shift of more than one nucleus , in which case they are ambiguous (see 
section 5.2.2). Alternatively, some NOE crosspeaks could not be matched to any 
known (assigned) nucleus and chemical shift. These unmatchable peaks were 
usually either erroneously marked noise, or due to incomplete assignment in a 
poorly-defined region of the protein. 
NOE intensities were later classified and converted to a distance in Angstroms 
(A), according to the categories listed in table 5.1. 
NOE category Relative intensity boundary Interproton distance (A) 
Strong > 3.0 < 2.7 
Medium > 1.5 < 3.3 
Weak > 0.3 < 5.0 
Very weak > 0.0 < 6.0 
Table 5.1: A table of NOE distance categories and relative intensities, which are 
converted to interproton distances using the connect script in AZARA[134]. 
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5.2.1 NOE to distance conversion 
The calibration of NOE intensity to distance restraint depends on the individual 
system being studied. In general, the validity of using a particular calibration 
method may be determined by analysing the distribution of NOE violations in the 
resulting structures. Violation "clustering" in certain residue types or particular 
secondary structure elements, or at distance boundaries, may indicate a poor 
relationship between the NOE calibration and the actual inter-nuclear distances. 
The low number of violations in the MBD2 MBD structures was taken as 
confirmation that the NOE calibration used was at least a conservative one. 
5.2.2 Ambiguous distance restraints 
Crosspeaks are unambiguous if they only have one possible assignment in each 
dimension. Ambiguous assignments are made when two or more nuclei pairings 
may be contributing to the crosspeak intensity. This ambiguity is common in 
proteins due to highly overlapped proton resonances. Erroneously assigning a 
crosspeak as unambiguous, can lead to incorrect and incomplete restraints. The 
distance restraint between two nuclei i and j, may be too short, as the contribu-
tion from a second NOE (i to k) is wrongly attributed to the first pairing. In 
addition, the distance restraint between nuclei i and k is lost, buried under the 
i-j NOE. This is illustrated in figure 5.1. A limitation of ANSIG is that each 
dimension of a crosspeak is either unambiguous or wholly ambiguous. It is not 
possible to describe a finite list of contributors to any one NOE, so that all res-
onances with similar chemical shifts are included as possibilities. This has the 
effect of weakening the restraints, but subsequent filtering and checking processes 
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Figure 5.1: The nature of ambiguous restraints. In this example, all HN protons 
have similar chemical shifts. The NOEs between Hi and 113 and Hi and Hk will be 
overlapped, so the assignment must be left ambiguous. In addition, a contribution 
from H will be included in the calculation, even though it is too far away for this 
to be genuine. Filtering (in later refinement steps) will probably discount H as 
a contributor. 
minimise spurious contributions (see 5.4.2). One problem with this approach, is 
that an ambiguous restraint has the potential to consistently restrain a pair of 
atoms in an under-restrained part of the structure, and consequently violate other 
(true) restraints. In other assignment software such as CCPNAnalysis [139], it is 
possible to assign a discrete number of atoms to an ambiguous crosspeak. 
5.3 Theory of structure calculation 
The aim of the structure calculation protocol, is to combine empirically derived 
stereochemistry and experimental data, to generate structures which satify all the 
restraints. The structure calculation method is molecular dynamics in Cartesian 
space, using simulated annealing. As it is not possible to explore all conforma- 
103 
tions of a molecule, the method provides an efficient minimisation strategy by 
monitoring the internal energy of the system. The conformations which satisfy 
the restraints with the lowest possible energy, are the best solutions to the prob-
lem, and have the highest probability of representing the true structure of the 
molecule. 
5.3.1 Simulated annealing 
The concept of simulated annealing (SA) is based on the way in which liquids 
freeze [140]. The annealing process starts with a high temperature "melt", which 
is slowly cooled so as to maintain thermodynamic equilibrium across the system. 
As cooling progresses, the system becomes more ordered, gradually approaching 
a theoretical "frozen" state. If the starting temperature is too low or the cooling 
process carried out too rapidly, then the system may become trapped in a region 
of local minimum energy. This must be avoided as the aim is to arrive at the 
global minimum energy state, and so solve the particular problem. 
In the original protocol, the SA algorithm compared each state of a system to 
a neighbouring state, which differed in a small, defined way from the initial con-
dition (see [141] for generalised example). The probability of the system moving 
to the neighbouring state was weighted according to the internal energy of each 
state; the system tended to move towards lower energy. Important parameters 
to be defined were the neighbourhood function, the transition probabilities and 
the annealing schedule. The SA protocol used in this thesis, however, is more 
straight-forward, and simply involves the slow removal of kinetic energy. This 
is achieved by lowering the effective temperature or by increasing the force con- 
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stants on the restraints. In all cases, the annealing schedule is limited by the 
computational time available; an unavoidable limitation on finding the global 
minimum. 
5.3.2 Molecular dynamics 
Molecular Dynamics (MD) is a computer simulation technique used to sample 
the potential conformations of a system, for a given set of restraints [142] and 
internal energy. Since the potential energy is the sum of all empirical and exper-
imental energy terms, the contribution of each of these terms to the total can be 
varied. The MD protocol is thus designed to reliably represent the changes in the 
conformation of a molecule over time. Experimental distance restraints derived 
from NOESY spectra are incorporated into the structure calculation along with 
information from a forcefield, (the non-experimentally derived restraints). The 
forcefield defines aspects of the covalent structure of a molecule, such as bond-
lengths, chirality, and non-bonded interactions. The parallhdg5.3 forcefield was 
used in this project [143]. 
5.4 Crystallography and NMR system 
The Crystallography and NMR System (CNS) programs [144], were used to carry 
out the structure calculation protocol. CNS brings together distance restraints, 
the forcefield, and a molecular topology file which defines the protein sequence 
and chemical bonds. There are three main stages to the calculation process. The 
first involves random structure generation in Cartesian space. A minimisation 
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Figure 5.2: A flow diagram to illustrate the iterative structure calculation process. 
Path la was followed in the first round, subsequent rounds followed route lb. 
Once significant violations had been removed, the refining stages in path 2 were 
used to create more precise structures 
process is carried out on the van der Waals potential energy term, for heavy 
atoms only. In the second stage, these random structures are regularised by 
enforcing the correct local geometry on each individual residue. Chirality and 
planarity (improper) terms are introduced and the system undergoes two SA 
phases. The aim is to remove one possible cause of the system becoming trapped 
in local energy minima. Local energy barriers may be overcome by allowing 
random swapping of prochiral groups. The final stage is a refinement process in 
which the whole system is cooled, and undergoes two further SA stages. Prochiral 
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groups such as methylene protons are swapped to give the lowest contribution to 
NOE energy. 
Structures from all three stages are written as Protein Data Bank (PDB) files 
[101], but generally only the refined structures are analysed in the next stage. 
5.4.1 Structure analysis 
The structure calculation process is iterative and involves several rounds of gener-
ating structures, analysing them, making changes to the restraints and repeating 
the calculations. An overview is given in figure 5.2. The first round of structure 
calculation was atypical. Only 10 refined structures were generated in order to 
quickly identify major violations. Violations can be thought of as unsatisfied re-
straints, in this case, inter-nuclear distances in the structure which do not fit the 
intensity of their NOEs. Deviations from experimental distance values of more 
than 0.5A, were classified as a violation. A common reason for violations is mis-
assignment of NOESY crosspeaks, due to typographical or judgement errors, and 
poor crosspeak placement, giving incorrect intensities. The first round analysis 
quickly identified some violations of this type, which were easily eliminated. See 
path la in figure 5.2. 
From round 2 onwards, the refined structures were ranked according to their 
total energy and a subset of structures chosen to be analysed (path ib, figure 5.2. 
The subset is made up of structures whose total energy is below a defined thresh-
hold. The definition is made for each set, where a sudden increase in energy is 
observed. Typically, each structure calculation round generated 30-50 structures, 
of which 80% formed the low energy subset. These were analysed as before, taking 
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into account additional reasons for the occurrence of violations. Violations may 
arise due to overlapping crosspeaks where it's difficult to determine how much of 
the intensity is due to a particular nuclei pair. Violations may also result from 
ambiguous crosspeaks, due to inclusion of all possible contributors (see section 
on Ambiguous NO Es). If false restraints are generated in an otherwise relatively 
unrestrained part of the molecule, then true contributions may be violated, in the 
attempt to satisfy the erroneous restraints. After several rounds of identifying 
and removing violations, the next step is to refine the structures. 
5.4.2 Refining the structure 
Two processes, filtering and checking are employed to refine the structures. Fil-
tering is a method of limiting the ambiguity in ambiguously assigned crosspeaks. 
By comparing the restraints with low energy structures, the contributors to each 
NOE are ranked according to their percentage contribution. The percentages 
are added up until a defined total is reached, after which, any remaining con-
tributions are discarded. Another round of calculations is then performed with 
these filtered restraints, and the process repeated. The filtering level started at 
99% (in which the final 1% of contributors was discarded) and was decreased 
in subsequent rounds. The MBD2 MBD structures were filtered three times at 
99%, then at 98%, and finally at 95%. Checking removes duplicate restraints that 
arise from symmetry related crosspeaks. The less intense NOE is discarded in 
each case. New structures were generated from filtered and checked NOEs, and 
then a subset was used as the comparison structures in subsequent rounds (see 
path 2 in figure 5.2). 
Description Value 
Total NOEs 1960 




short range 211 
long range 348 
Average no. violations >0.5A: 1 
Max. no. of violations per structure: 3 
Max. distance contraint violation: 0.9A 
Deviations from idealised geometry: 
Bond lenghts: 0.047A(0.0025 r.m.s.d.) 
Bond angles: 0.41A(0.019 r.m.s.d.) 
Impropers: 0.31A(0.026 s.d.) 
PROCHECK Ramachandran plot stats (151-204): 
Most favoured 64.7% 
Additionally Allowed 32.2% 
Generously Allowed 2.5% 
Disallowed 0.5% 
R.m.s.d from the mean (residues 151-204) 
Backbone atoms 0.63A 
All heavy atoms 0.95A 
R.m.s.d from the mean (residues 151-168 & 178-204) 
Backbone atoms 0.49A 
All heavy atoms 0.84A 
Table 5.2: A table showing the statistics relating to the final structures of the 
MBD from MBD2. All values relate to the low energy ensemble, which comprises 
37/45 final calculated structures, but in some cases flexible residues have been 
excluded from the statistics. 
5.5 Results of calculations 
1960 NOEs were used to solve the structure of the MBD from MBD2 (residues 
153-224). This excludes two non-native residues and five of six N-terminal his-
tidines, for which no NMR assignments could be found. The final round of 
structure calculation produced 45 structures, of which 37 had similar energies 
and were included in the final ensemble of structures (see figure 5.4). An energy 
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Figure 5.3: Plot of Total energy (in red) and NOE energy (in green) for each of 
the 45 final structures, ordered according to the total energy. The low energy 
ensemble is made up of structures 1-37. 
ure 5.3. There are 37 NOE violations above 0.5 in the 37 structure ensemble, 
and a maximum of 3 violations in any one structure. The convergence level is 
high, (greater than 80%), which indicates a high level of precision in the struc-
ture. Full statistics for the final ensemble are shown in table 5.1. PROCHECK 
[145] statistics were calculated using residues 151-204 (and an additional r.m.s.d 
calculated exclusing loop Li). The 20 C-terminal amino acids were excluded as 
15N spectral linewidths suggested that there is genuine flexibility in this region. 
Broadened '5N-HSQC peaks were also observed for Li loop residues (see Chapter 






Figure 5.4: An ensemble of the 37 lowest energy structures calculated using CNS. 
All assigned amino acids (151-224) are included here, and the ensemble has been 
rotated between each depiction, as indicated. The backbone of residues shown in 
black was used for fitting purposes in MOLMOL [146], whilst blue regions were 
excluded due to their flexibility. 
5.5.1 MBD2 MBD fold 
The MBD2 MBD has the typical wedge-shaped, a//3-sandwich fold, common 
to all the MBD structures solved so far. The secondary structure elements are 
identical to those of the MBD1 MBD, with a four-stranded, twisted /3-sheet (131, 
residues 153-156; /32, 162-168; /33, 178-184; /34, 188-191) and a long loop (168-
178) on one side. A short helix (194-201) and C-terminal hairpin loop (207-217) 
make up the other face. Although much of the backbone is well-defined, and 
similar to the MBD1 structure, there are some notable differences in the loops. 
The C-terminal 20 residues are poorly ordered in the MBD2 structure, due to 
incomplete assignment in this region. In spite of this, a /3-hairpin structure, like 
that of MBD1, is identifiable in an ensemble of the lowest 10 energy structures 
(see figure 5.5). The long loop, Li, between /3-strands  2 and 3, appears to be 
















Figure 5.5: Backbone superposition of the 10 lowest energy structures of the 
MBD2 MBD (made using MOLMOL [146], labelled with amino acid numbers, 
and a cartoon representation (made using MoiScript [147]) showing the secondary 
structure elements. The superposition was done as for figure 5.4. 
the extension of each flanking 3-strand, and has a ladle shape. 
The MBD has a well-defined hydrophobic core, made up of Leu158, Tp162, 
Va1180, Tyr182, Phe190, Leu196, and Leu200. Other C-terminal residues, Leu206 
and Phe211 may also form part of the core, although they are not so well-defined 
in this structure. The MBD2 MBD has three solvent-exposed, aromatic amino 
acids. Tyr181 is completely conserved throughout the mammalian MBD family, 
apart from in MBD3, and the position occupied by Phe183 is hydrophobic in 
all family members apart from MBD1. Tyr199 is completely conserved and may 
form a lid on the core whilst being largely solvent-exposed. Another conserved 
group of amino acids form a basic surface on one side of the molecule. Arg 169, 
Lys170, Lys177, Lys189, Argi9i, K193 and Arg212 are mostly clustered between 
helix o1 and loop Li, extending along the linker between ad and /34. This is 
the region in which DNA-binding occurred in MBD1 [100]. Figure 5.6 shows 




Figure 5.6: A: Overlay of the sidechains from the 10 lowest energy structures of 
the MBD2 MBD. A single backbone (in black) is shown and the disordered, C-
terminal residues (218-224) have been omitted for clarity. B: An ensemble of 10 
modelled structures of the MBD2 MBD, based on the MBD1 structure. The back-
bone (black) is shown for all modelled residues (151-216). For both images: Hy-
drophobic core residues are shown in dark blue (aromatics) and green (aliphatics); 
solvent-exposed aromatic residues are in light blue; positively charged residues 
forming the basic surface are coloured red. 
charged DNA-binding face. 
5.6 Comparison with predicted model 
Due to the high level of sequence similarity between MBDs, a model of the MBD2 
MBD was created, using the MBD1 MBD structure as a template. The alignment 
used for model building was the same as that shown in Chapter 1, figure 1.3. 10 
models were generated using MODELLER 8v1 [148, 149], and the ensemble is 
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shown in figure 5.6. 
The model of the MBD2 MBD, has the same overal fold as the calculated 
NMR structure, except that it is more extended. This is due to a relatively 
elongated helix (al), and less rigid loop (Li), in the MODELLER structure. 
The orientation of core sidechains agrees well between predicted and calculated 
models, although some of the C-terminal residues are better defined in the former. 
This is because of the higher degree of precision for MBD1 in this region. The 
orientation of the Trp162 sidechain differs in the two models. This appears to be 
a genuine difference between MBD1 and MBD2, but why this should be (in one 
of the most conserved, core residues) is not clear. 
5.6.1 DNA-binding loop 
The more rigid structure of the loop in MBD2, is attributable to many ambiguous, 
short-range NOEs between loop residues. These, together with a small number 
of long-range NOEs (2 unambiguous, 9 ambiguous), from Li to residues in the 
hairpin, are also responsible for the ladle-shape. In figure 5.7, the MBD2 MBD 
structure has been superimposed onto the MBD1 structure from the MBD:DNA 
complex [100]. Free MBD2 has a DNA-binding face which more closely resembles 
that of MBD1 in complex, than free MBD1. 
5.7 Conclusion 
The structure of the MBD from MBD2, was solved with good internal consistency, 
and the fold agrees well with other published MBD structures. A comparison 
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with models reveals that some differences in the loop, Li, were not predicted 
based on sequence similarity alone. Although highly similar to MBD1, the MBD2 
MBD appears to have a pre-formed DNA-binding loop, which may account for 
differences in the efficiency of methyl-CpG recognition, and DNA-binding. 
Figure 5.7: Overlay of the backbone of three MBD structures: MBD1 MBD 
(cyan) from the MBD:DNA complex, free MBD2 MBD (blue), and a model of the 
MBD2 MBD, based on the free MBD1 structure (yellow). The DNA backbone is a 
beige line; meCpGs and the five residues from MBD1 that form the hydrophobic 
meDNA recognition patch, are shown as sticks. Cytosines are in orange, with 
methyl groups coloured red; Va120, pink; Arg22 and Arg44, blue; Asp 32, green 
and Tyr34, magenta. The loop, Li, forms a major part of the DNA binding 
interface. In MBD2, it's conformation more closely resembles that of the loop in 




6.1 Structural work 
6.1.1 MBD structure 
NMR was used to solve the structure of the free MBD from MBD2. Structure 
statistics, generated using PROCHECK [145] and by analysis of the NOE re-
straints, indicate good quality with a low backbone r.m.s.d. of 0.45A. Ramachan-
dran plot statistics for structured residues (151-204, excluding the C-terminus), 
include 99.5% of residues in favoured and allowed regions. The overall fold of 
the domain is similar to three previously solved MBDs or MBD-like domains 
[100, 102, 98], but most closely resembles the MBD of MBD1, with which it has 
the highest sequence similarity. 
A notable difference is found in the long loop, Li, which adopts a smaller 
range of conformations and appears to be more rigid than the equivalent region 
in MeCP2 and MBD1. The structure of the free MBD overlays well with the 
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structure of the MBD1 MBD in the bound state with DNA (see figure 5.7), so it 
is possible that MBD2 has a pre-formed DNA-binding loop. However, residues 
170-177, around the long loop, gave unusually sharp NMR signals, resembling 
those observed at both termini. This suggests that the loop is in fact dynamic. At 
the relatively low temperature (288K) used in these experiments however, NOEs 
from loop residues are seen. These include a large number ( 40 per residue) of 
short-range ambiguous NOEs between loop residues, and a few (9 ambiguous, 2 
unambiguous) NOEs between Li and the C-terminal hairpin loop. In contrast, 
NMR data used to solve the MBD1 MBD structure was collected at 303K, and for 
the MeCP2 MBD, at 291K. At these temperatures, particularly for MBD1, which 
was determined at 15K higher temperature, the faster motion of the loop may 
have resulted in NOE averaging, effectively eliminating restraints in this region. 
How then, is it possible that a limited set of loop conformations are observed in 
the MBD2 MBD structure? Due to the relationship between NOE intensity and 
internuclear distance', a significant NOE may result from a conformation that is 
present only a small proportion of the time. If that NOE produces a restraint 
that can only be satisfied on one face of the protein, however ambiguously, the 
subset of structures will be biased towards that side. In the MBDs, there is an 
absence of structured residues on the back face of loop Li, with which to form 
NOEs. This could prevent effective sampling of a whole range of alternate loop 
conformations. The presence of 2 unambiguous restraints between Li and the 
hairpin indicates that this conformation is a likely, but not necessarily the only, 
possibility. 
'to a first approximation, NOEs are proportional to r 6, where r is the internuclear distance 
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6.1.2 MBD:DNA complex 
Titration of methylated DNA into a labelled NMR sample allowed analysis of 
perturbations of the backbone NH chemical shifts. The observed effects were as 
expected from previous work on MeCP2 and MBD1. Although the Li loop region 
in the MBD2 MBD may be more structured than in either of the two other pro-
teins, large chemical shifts were still observed for almost all loop residues. This 
indicates that the loop conformation is still significantly altered by methylated 
DNA binding. Evidence of reduced flexibility was also found in the sequential 
assignment of the MBD:DNA complex. CBCA(CO)NH and HNCACB connec-
tions were much improved compared to the free domain. Figure 6.1 maps the 20 
residues with the largest chemical shift changes onto the solved structure of the 
MBD. Almost all the residues are found in the DNA-binding interface proposed 
in the MBDi:DNA structure [100], including the five amino acids which form 
the methyl-recognising hydrophobic patch. Five residues (Lys 164, Glu 165, Phe 
190, Gln 195 and Leu 196) are in regions that might reasonably be expected to 
undergo significant chemical shift changes, as neighbouring residues make contact 
with the DNA. The largest changes were observed for certain residues at the base 
of the loop: lie 168, Gly 172, Ser 174 and Ala 175. Similar patterns of altered 
chemical shift were observed for both MBD2 and MBD4 MBDs, and these agree 
well with published data for MBD1. There is no evidence to suggest that the 
actual mode of methyl recognition varies between proteins. 
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Figure 6.1: The largest changes in chemical shift, induced upon DNA binding, 
mapped onto the solved MBD structure. These include the five residues that 
form the hydrophobic, methyl-recognition patch (sidechains in magenta) as well 
as 15 other residues (sidechains in blue). Rotation between each depiction is as 
indicated. 
6.2 Methylated DNA binding 
Surface Plasmon Resonance (SPR) studies in this thesis provide the first reliable 
binding contants obtained for a MBD:DNA interaction. This is possible because 
the Biacore system allows determination of the rate constants to a high level of 
accuracy and reproducibility. Previous attempts to quantify the affinities have 
been by band shift experiments, using longer oligos with multiple methylation 
sites. These did not give information about any differences in recognition of a 
single meCpG. 
MeCP2 and MBD4 MBDs have a higher affinity for methylated DNA, when 
compared to MBD2. None of the proteins bound unmethylated DNA, and each 
MBD had a similar affinity for all three methylated oligos. This suggests that the 
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integrity of a symmetrically methylated CpG is unimportant for the MBD:DNA 
interaction. 
A recent publication reports the use of molecular dynamics simulations, start-
ing from the MBD1:DNA structure, to investigate the finer details of methyl 
recognition [150]. In that study, the second methyl group was found to contribute 
an almost negligible amount to the total binding energy, which supports the con-
clusion that there is no difference in MBD affinity for symmetrically methylated, 
hemimethylated and CpG:TpG mismatched oligonucleotides by SPR. 
The study found that the overal mode of DNA binding remained unchanged, 
but that one conserved residue in the DNA-binding interface, Asp 32 (Asp 179 in 
MBD2), could form a direct cytidine base contact, where before it had not. Two 
forms of direct contact were observed: In the minor form (for about 1 ns of the 
simulation), Asp 32 bridges the two methylated cytosines with its carboxylate 
group. This is stabilised by a hydrogen bond between one of the carboxylate 
oxygen atoms and the nearby hydroxyl group of tyrosine 34 (Tyr 181 in MBD2). 
In the major conformation, two carboxylate hydrogen bonds are made with the 
guanidinium group of Arg 22 (Arg 169 in MBD2) and one with N4 of an un-
methylated, flanking cytosine. 
These data suggest that there is a reasonable degree of flexibility within the 
recognition mechanism, and that these motions are not detectable on the NMR 
timescale (milliseconds). Such precise adjustments indicate that the methyl recog-
nition mechanism may be more complex than previously thought. 
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6.2.1 Length and sequence dependence of MBD binding 
By SPR it was observed that none of the MBDs bound a methylated 10-mer. The 
apparent dependence, of MBD:DNA binding, on the length of the oligonucleotide, 
will require further investigation. It could simply be due to steric hinderance with 
the streptavidin chip matrix. 
A recent study found that the MeCP2 MBD specifically recognises an AT-rich 
region at least 4 b.p. away from the methylated CpGs [50]. The same study also 
found that while MBD2 was able to compensate for morpholino depleted MeCP2 
at over half its binding sites, the reverse was not true. MeCP2 was only able 
to bind to 3 out of 25 sites previously occupied by MBD2. MeCP2 has been 
found to possess an AT hook C-terminal to the MBD, so it was thought that this 
domain might be responsible for the observations. However, a deletion analysis 
found that the MBD plus a 13 residue N-terminal extension, was the minimum 
required for AT-specific recognition. It is difficult to reconcile this information 
with the methyl-recognition mechanism that is currently understood. The domain 
itself is not large enough to have an additional DNA contact region, and the 13 
residue extension is on the opposite side of the domain, away from the DNA-
binding interface. It is perhaps just possible that an unstructured N-terminal 
extension may reach to an AT rich region, but this seems unlikely. AT and 
meCpG recognition therefore constitute two steps in the binding mode. 
The reason why MeCP2 cannot compensate for MBD2, may be due to other 
domains outside the MBD, which stabilise binding to certain DNA sequences. 
Various different interaction partners, particular to each protein, may also have 
this effect. Either of these possibilities could explain a preference for specific 
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promoter regions. 
6.3 Future structural investigations 
6.3.1 MBD2 MBD:DNA complex 
The solution structure of the MBD2 MBD:DNA complex could be solved by 
NMR, but sample stability is the main barrier to collecting adequate data. An 
attempt has been made to design more stable constructs, by using data from 
limited proteolysis. In order to produce these however, a large scale screen of 
MBD2b for suitable fragments will be necessary. An alternative is to produce 
mutants, or carry out chemical modifications that stabilse the MBD fold. Alky-
lation of the single N-terminal cysteine was achieved but had no effect on the 
lifetime of the sample. 
Essential to solving the structure of the MBD:DNA complex, is optimisation 
of X-filtered experiments [138, 151]. These are used to measure intermolecular 
NOEs, for example between '5N, '3C-labelled protein and unlabelled DNA. NOEs 
may be measured from 13C-1H to all '2C- and '5N-attached protons, but not to 
those that are 13C-attached. Since the protein is labelled, then observed NOEs 
to '2C-'H, must all be intermolecular and from the DNA. Intermolecular NOEs 
define individual interatomic contacts in much more detail compared to the more 
general information obtained from chemical shift perturbation experiments. A 
common problem for weak complexes, however, is that intermolecular NOEs are 
averaged out across the ensemble of structures, so that they effectively dissappear 
from the spectrum. If there is highly variable local geometry at the binding 
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surface, as suggested by molecular dynamics simulations [150], this could account 
for the difficulties experienced. 
It would also be interesting to compare the structure to that of the MBD in 
complex with unmethylated DNA, if such a complex will form under conditions 
required for NMR. Titration of the MBD1 MBD with an unmethylated oligorner 
did not appear to produce a complex [99], but the proteins may be sufficiently 
different, that the experiment is worth repeating with MBD2. 
6.3.2 Loop flexibility 
The structure and function of the loop Li, is worthy of further investigation, to 
establish if it is a cause of observed differences in MBD:DNA affinity. Both local 
and global protein flexibility can be investigated using the relaxation properties 
of backbone amides. '5N-relaxation experiments could be used to find out how 
flexible the Li loop is, on a pico- to millisecond timescale. Using the ratio of the 
longitudinal to transverse relaxation times', backbone dynamics of the MBD2 
MBD may be obtained and compared to those of other MBDs. 
6.3.3 Prospects for crystallography 
Attempts to crystallise the MBD2 MBD:DNA complex were unsuccessful. So far, 
no crystal structures of MBD-like folds have been published, so NMR is there-
fore the technique of choice for investigating this interaction. Ongoing work to 
crystallise the MeCP2 MBD:DNA complex has attempted to exploit the recently 
discovered sequence specificity of MeCP2 [50] in choosing the DNA oligomer. 
2T1/T2 ratio 
123 
Co-crystallisation of the MeCP2 MBD:DNA complex has been achieved, but res-
olution below 4A remains elusive [152]. Although the crystallographic approach 
has been unfruitful, it is still attractive because of the potential to discover the 
details of methyl recognition involving the termini of arginine side chains. It is not 
always possible to assign or even detect these in NMR experiments. On the other 
hand, if the mechanism involves a series of recognition steps and rearrangement 
of the MBD on the DNA, then a crystal structure will not necessarily provide 
information that distinguishes between MBDs. Work on the full-length proteins 
is likely to be hampered by unstructured regions connecting the various different 
motifs. These make the MBDs too flexible for crystallisation (see figure 6.2). 
6.3.4 MBD2:protein interactions 
Possibilities for future projects include solving the structure of selected regions of 
MBD2, in complex with various binding partners. One region of MBD2, 211-262, 
(363-414) specifically binds to hp66 [74], and is predicted to fold into a helical 
region. It has a high degree of similarity to a coiled-coil and probable protein-
protein interaction domain [153] (see figure 6.2), and may provide the foundation 
of a discrete region of MBD2. This makes it a likely target for co-crystallisation 
and NMR studies of the complex with p66. 
It may also be possible to understand how the repressive function of MBD2 is 
modulated by its interactions with certain proteins. MBDin reactivate promoters 
that have been silenced by MBD2 [83], and acts antagonistically to MIZF, which 
enhances MBD2-mediated repression [78]. Each partner binds to discrete regions 
of MBD2: MBDin to the C-terminus, residues 209-262 (361-414), and MIZF to a 
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region which overlaps with the C-terminal end of the MBD, residues 53-154 (205-
306). It will, however, be difficult to evaluate these complexes in the context 
of the full-length protein structure (see section 6.3.3), which may be crucial to 
understanding the fine-tuning of the MBD2 gene-silencing mechanism. 
It is hoped that dissecting these interactions will reveal much more about 
the various roles of MBD2, in effecting gene silencing due to altered chromatin 
architecture. 
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Figure 6.2: Ab initio structure prediction for full-length MBD2a, using the struc-
ture prediction tool, 3D-PSSM [153]. The amino acid sequence is shown on the 
top line, and regions predicted to be a defined secondary structure, are shown 
as follows: Alpha helices are denoted by H (blue), beta-strands by E (orange), 
and random coil, by C (grey). The confidence value of the prediction is shown as 
a number between 0 (lowest) and 9 (highest), on the line below the prediction. 
The secondary structure of the MBD, as determined in this project, is indicated 




A.1 Production of competent E. eoli 
A.1.1 The CaC12 method 
Inoculate 50m1 LB, 1:50 from an overnight culture of E. coli, and grow to 
A600 0.5. 
Spin down at 3000 r.p.m. for 10 minutes. 
Resuspend the cells in 20m1 ice cold, 50mM CaC12, and leave on ice for 20 
minutes, before spinning down again. 
Resuspend the cells in 2m1 ice cold, 50mM CaC12, and leave on ice for 2-24 
hours maximum. 
A.2 Production of labelled samples for NMR 




Make up to 1L with deionised H20 
Per 500m1 flask of M9 minimal media: 
lOOml 5x M9 
lml 1M MgSO4 
50il 1M CaCl2 
200l 5mM FeC13  
0.5g 15NH4C1 or 0.6g (15NH4 )2SO4 
1.5g glucose, '3C-labelled or unlabelled as required 
Make up to 500ml with deionised H20 
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A.3 Production of deuterated NaPi buffer 
50m1 of a buffer solution of 50mM NaPi, 50mM Nacl pH 7.0, was dessicated on 
a rotary evaporator overnight (full vacuum, 300C). The buffer powder was then 
made up to 50m1 using 99% D20 (Sigma). The protein solution was concentrated 
and then buffer-exchanged into the 99% deuterated NaPi buffer using a 6ml 
vivaspin tube with a 5K cut-off (Vivascience). This was done twice so as to achieve 
a 500-fold dilution of any H20 present. 2ml of 99.9% NaPi buffer was made by 
dissolving the required amount of dessicated buffer in 99.9% D2 0 (Sigma). The 
process of buffer exchange was repeated with 99.9% deuterated NaPi buffer, to 




B.1 Processing scripts 
The following are examples of scripts used to process multidimensional NMR data 
with AZARA. 
B.1.1 FT processing of 2D '5N HSQC 
script-corn 1 
complex 
gaussian_sw 20 1.3 0 
zerofill 1 
fft 
phase 0 25785 




















avance 12 16 























phase 90 -180 
reduce 
end-script 













phase 90 -180 
end_maxent 
B.1.3 Perl script to analyse MEM plane convergence 
This script checks the convergence status of each plane, as reported in the m.log 
file. If a plane has not reached convergence ("status = 0"), then the following 
plane number is printed, allowing easy identification of non-converged planes. 
#! /bin/perl 
open (IN,"m.log") II die "File bogus:$!"; 
$i=0; 
while (<IN>) { 
$Buff [$i] =$_ 
if(($i !=0)&&($= m/working/)){ 
if($Buff[($i-2)] 	rn/status = 0/) 
{ 
print "$Buff [$i]"; 
} 
undef @Buff; 
$i = 0; 
I' 
} 
if($Buff[($i-2)] 	rn/status = 0/) 
{ 




B.2 Contour generation scripts 
The following script generates contours which can be read by ANSIG. One contour 
description file is needed per 'view' of the data, so that for 3D data, two separate 
contours files are required. 
input spc.par.ref 
output cnt_complex 
dims 1 2 
levels 300000 -300000 
levels 600000 -600000 
levels 1200000 -1200000 
levels 2400000 -2400000 
levels 4800000 -4800000 
levels 9600000 -9600000 
levels 19200000 -19200000 
levels 38400000 -38400000 
levels 76800000 -76800000 
levels 153600000 -153600000 
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Appendix C 
Chemical Shift Tables 
C.1 MBD2 MBD chemical shifts 
Residue Residue no. 'H 6 (ppm) Attached heteroatom 6 (ppm) 
His 151 HA 4.6644 CA 55.7340 
His 151 HB1 3.0489 CB 30.4725 
His 151 HB2 3.2099 GB 30.4725 
His 151 HD2 7.0291 CD2 120.1173 
His 151 HE1 -99 GEl -99 
His 151 HN 8.5769 N 120.3832 
His 151 HD1 -99 ND1 -99 
His 151 HE2 -99 NE2 -99 
Ala 152 HA 4.5818 CA 52.0910 
Ala 152 HB1 1.2345 GB 19.8585 
Ala 152 HB2 1.2345 GB 19.8585 
Ala 152 HB3 1.2345 GB 19.8585 
Ala 152 HN 8.2994 N 125.3200 
Met 153 HA 4.7723 GA 54.2948 
Met 153 HB1 2.0536 GB 35.4305 
Met 153 H132 2.1889 GB 35.4305 
Met 153 HE1 -99 GE -99 
Met 153 HE2 -99 GE -99 
Met 153 HE3 -99 GE -99 
Met 153 HG1 2.6213 GG 31.7143 
Met 153 HG2 2.6213 CG 31.7143 
Met 153 HN 8.7694 N 119.7930 
Asp 154 HA 4.6671 GA 55.7302 
Asp 154 HB1 2.5891 GB 41.3627 
Asp 154 HB2 2.7336 GB 41.3627 
Asp 154 HN 8.6777 N 121.8010 
Gys 155 HA 5.1931 GA 56.0106 
Gys 155 HB1 2.8017 GB 28.0069 
Gys 155 HB2 2.9171 GB 28.0069 
Gys 155 HN 8.3187 N 121.2535 
Pro 156 HA 4.5923 GA 64.6403 
Pro 156 HB1 2.0585 GB 32.2005 
Pro 156 HB2 2.4092 GB 32.2005 
Pro 156 HD1 3.7910 CD 51.5238 
Pro 156 HD2 4.0580 CD 51.5238 
Pro 156 HG1 2.0500 CG 27.0280 
Pro 156 HG2 2.0500 CG 27.0280 
Ala 157 HA 4.2660 GA 53.0040 
Ala 157 HB1 1.4870 GB 20.0947 
Ala 157 HB2 1.4870 GB 20.0947 
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Residue Residue no. 'H 6 ppm) Attached heteroatom 6 (ppm) 
Ala 157 HB3 1.4870 GB 20.0947 
Ala 157 HN 7.4833 N 118.1702 
Leu 158 HA 4.2684 CA 52.0250 
Leu 158 HB1 0.8960 CB 40.8548 
Leu 158 HB2 1.4622 CB 40.8548 
Leu 158 HD11 -0.3871 CD1 21.3382 
Leu 158 HD12 -0.3871 CD1 21.3382 
Leu 158 HD13 -0.3871 CD1 21.3382 
Leu 158 HD21 0.3389 CD2 26.3615 
Leu 158 HD22 0.3389 CD2 26.3615 
Leu 158 HD23 0.3389 CD2 26.3615 
Len 158 HG 1.1632 CG 26.8223 
Len 158 HN 7.7237 N 119.1377 
Pro 159 HA 4.6396 CA 62.2260 
Pro 159 HB1 1.9338 CB 29.8250 
Pro 159 HB2 2.6029 CB 29.8250 
Pro 159 HD1 2.5239 CD 50.0594 
Pro 159 HD2 3.1235 CD 50.0594 
Pro 159 HG1 1.8094 CG 27.7590 
Pro 159 HG2 1.8094 CG 27.7590 
Pro 160 HA 4.3554 CA 64.6262 
Pro 160 HB1 1.8825 CB 31.9757 
Pro 160 HB2 2.3555 CB 31.9757 
Pro 160 HD1 3.6324 CD 50.2838 
Pro 160 HD2 3.8944 CD 50.2838 
Pro 160 HG1 2.0670 CG 27.9922 
Pro 160 HG2 2.1601 CG 27.9922 
Gly 161 HAl 3.6729 CA 45.3992 
Gly 161 HA2 4.2314 CA 45.3992 
Gly 161 HN 8.6522 N 111.7470 
Trp 162 HA 4.6972 CA 59.2150 
Tp 162 HB1 3.1265 CB 30.4974 
Tp 162 HB2 3.3011 CB 30.4974 
Trp 162 HD1 7.3423 CD1 127.5670 
hp 162 HE3 7.3966 CE3 120.4127 
rI p  162 HH2 6.2474 CH2 124.0740 
Trp 162 HZ2 7.4370 CZ2 113.6818 
Trp 162 HZ3 6.4834 CZ3 121.8910 
Trp 162 HN 7.8025 N 121.3900 
Trp 162 HE1 10.8199 NE1 111.2979 
Lys 163 HA 5.2340 CA 54.7264 
Lys 163 HB1 1.6673 CB 37.9311 
Lys 163 HB2 1.7043 CB 37.9311 
Lys 163 HD1 1.3796 CD 29.2495 
Lys 163 HD2 1.4655 CD 29.2495 
Lys 163 HE1 2.7930 CE 42.3500 
Lys 163 HE2 2.7930 CE 42.3500 
Lys 163 HG1 1.3286 CG 25.0675 
Lys 163 HG2 1.3286 CG 25.0675 
Lys 163 HN 8.8908 N 120.3555 
Lys 163 HZ1 -99 NZ -99 
Lys 163 HZ2 -99 NZ -99 
Lys 163 HZ3 -99 NZ -99 
Lys 164 HA 4.9291 CA 54.7059 
Lys 164 HB1 1.5036 CB 36.5572 
Lys 164 HB2 1.6521 CB 36.5572 
Lys 164 HD1 1.4467 CD 29.0057 
Lys 164 HD2 1.5667 CD 29.0057 
Lys 164 HE1 2.7331 CE 41.8890 
Lys 164 HE2 2.7331 CE 41.8890 
Lys 164 HG1 0.7141 CG 24.3275 
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Lys 164 HG2 0.8136 CG 24.3275 
Lys 164 HN 9.2145 N 122.4179 
Lys 164 HZ1 -99 NZ -99 
Lys 164 HZ2 -99 NZ -99 
Lys 164 HD -99 NZ -99 
Glu 165 HA 4.7586 CA 55.2610 
Glu 165 HB1 1.7616 CB 34.9053 
Glu 165 HB2 2.0299 CB 34.9053 
Glu 165 HG1 2.0957 CG 36.6602 
Glu 165 HG2 2.1562 CG 36.6602 
Glu 165 HN 9.2935 N 128.5810 
Gin 166 HA 5.1023 CA 54.7432 
Gin 166 HB1 1.7581 CB 31.9631 
Gin 166 HB2 1.8942 CB 31.9631 
Gin 166 HG1 1.9999 CG 36.5735 
Gin 166 HG2 2.0776 CG 36.5735 
Gin 166 HN 8.4923 N 124.5695 
Val 167 HA 4.3662 CA 61.1991 
Val 167 HB 2.0508 CB 34.4603 
Val 167 HG11 0.8957 CG1 21.0730 
Val 167 HG12 0.8957 CG1 21.0730 
Val 167 HG13 0.8957 CG1 21.0730 
Val 167 HG21 0.8957 CG2 21.0730 
Val 167 HG22 0.8957 CG2 21.0730 
Val 167 HG23 0.8957 CG2 21.0730 
Val 167 HN 9.0551 N 125.8223 
Ile 168 HA 4.2007 CA 60.9413 
Ile 168 RB 1.7506 CB 38.3219 
Ile 168 HD11 0.7650 CD1 12.5736 
Ile 168 HD12 0.7650 CD1 12.5736 
Ile 168 HD13 0.7650 CD1 12.5736 
Ile 168 HG11 1.1312 CG1 27.9815 
Ile 168 HG12 1.4552 CG1 27.9815 
Ile 168 HG21 0.7987 CG2 17.3899 
Ile 168 HG22 0.7987 CG2 17.3899 
Ile 168 HG23 0.7987 CG2 17.3899 
Ile 168 HN 8.7292 N 128.5775 
Arg 169 HA 4.3894 CA 55.9981 
Arg 169 HB1 1.8422 CB 30.7510 
Arg 169 HB2 1.8422 CB 30.7510 
Arg 169 HD1 3.0567 CD 43.3530 
Arg 169 HD2 3.1818 CD 43.3530 
Arg 169 HG1 1.6507 CG 27.3398 
Arg 169 HG2 1.6507 CG 27.3398 
Arg 169 HN 8.7541 N 127.5865 
Arg 169 HE -99 NE -99 
Arg 169 HH11 -99 NI-11 -99 
Arg 169 HH12 -99 NH1 -99 
Arg 169 HH21 -99 NI-12 -99 
Arg 169 HH22 -99 NI-12 -99 
Lys 170 HA 4.3582 CA 56.8631 
Lys 170 HB1 1.7653 CB 33.4596 
Lys 170 HB2 1.9007 CB 33.4596 
Lys 170 HD1 1.6617 CD 28.9216 
Lys 170 HD2 1.6617 CD 28.9216 
Lys 170 HE1 2.9724 CE 42.0726 
Lys 170 HE2 2.9724 CE 42.0726 
Lys 170 HG1 1.4029 CG 24.9132 
Lys 170 HG2 1.4942 CG 24.9132 
Lys 170 RN 8.8765 N 124.2243 
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Lys 170 HZ1 -99 NZ -99 
Lys 170 HZ2 -99 NZ -99 
Lys 170 HZ3 -99 NZ -99 
Ser 171 HA 4.6061 CA 57.5645 
Ser 171 HB1 3.8050 CB 64.7327 
Ser 171 HB2 3.8516 CB 64.7327 
Ser 171 HN 8.0482 N 114.3088 
Gly 172 HAl 3.8955 CA 45.1314 
Gly 172 HA2 4.1807 CA 45.1314 
Gly 172 HN 8.6394 N 128.4930 
Leu 173 HA 4.2365 CA 56.4877 
Leu 173 HB1 1.6110 CB 42.1219 
Leu 173 HB2 1.6968 CB 42.1219 
Leu 173 HD11 0.8835 CD1 23.3074 
Leu 173 HD12 0.8835 CD1 23.3074 
Leu 173 HD13 0.8835 CD1 23.3074 
Leu 173 HD21 0.9293 CD2 25.0078 
Leu 173 HD22 0.9293 CD2 25.0078 
Leu 173 HD23 0.9293 CD2 25.0078 
Leu 173 HG 1.6761 CG 27.1256 
Leu 173 HN 8.5457 N 121.7170 
Ser 174 HA 4.4692 CA 57.7268 
Ser 174 HB1 3.9135 GB 63.2041 
Ser 174 HB2 3.9135 GB 63.2041 
Ser 174 HN 8.4364 N 114.3615 
Ala 175 HA 3.9146 GA 53.2730 
Ala 175 HB1 1.2697 GB 18.5068 
Ala 175 HB2 1.2697 GB 18.5068 
Ala 175 H133 1.2697 GB 18.5068 
Ala 175 HN 7.6921 N 123.6214 
Gly 176 HAl 3.7237 CA 45.1180 
Gly 176 HA2 4.1730 CA 45.1180 
Gly 176 HN 8.5960 N 128.4090 
Lys 177 HA 4.4562 CA 55.9843 
Lys 177 HB1 1.8675 GB 33.6823 
Lys 177 HB2 1.8675 GB 33.6823 
Lys 177 HD1 1.6644 CD 29.2508 
Lys 177 HD2 1.6644 CD 29.2508 
Lys 177 HE1 2.9863 GE 42.2345 
Lys 177 HE2 2.9863 CE 42.2345 
Lys 177 HG1 1.4201 CG 25.0517 
Lys 177 HG2 1.4267 CG 25.0517 
Lys 177 HN 8.1182 N 121.1616 
Lys 177 HZ1 -99 NZ -99 
Lys 177 HZ2 -99 NZ -99 
Lys 177 HZ3 -99 NZ -99 
Ser 178 HA 5.0381 GA 57.3042 
Ser 178 HB1 3.6908 GB 65.0975 
Ser 178 HB2 3.6908 GB 65.0975 
Ser 178 HN 8.5325 N 116.9395 
Asp 179 HA 4.9703 GA 53.7873 
Asp 179 HB1 2.4281 GB 44.3409 
Asp 179 HB2 2.4534 GB 44.3409 
Asp 179 HN 8.7731 N 123.1056 
Val 180 HA 4.5545 CA 61.4522 
Val 180 HB 1.7865 GB 34.1932 
Val 180 HG11 0.5099 GG1 21.5936 
Val 180 HG12 0.5099 GG1 21.5936 
Val 180 HG13 0.5099 GG1 21.5936 
Val 180 HG21 0.8477 GG2 21.8086 
Val 180 HG22 0.8477 GG2 21.8086 
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Val 180 HG23 0.8477 CG2 21.8086 
Val 180 HN 8.1156 N 121.5825 
Tyr 181 HA 5.3088 CA 54.9236 
Tyr 181 HB1 2.6036 CB 42.4050 
Tyr 181 HB2 2.7151 CB 42.4050 
Tyr 181 HD1 6.9016 CD1 133.2053 
Tyr 181 HD2 6.9016 CD2 133.2053 
Tyr 181 HE1 6.7064 CE1 118.1469 
Tyr 181 HE2 6.7064 CE2 118.1469 
Tyr 181 HN 8.5556 N 122.4151 
Tyr 182 HA 5.6294 CA 56.7410 
Tyr 182 HB1 2.8043 CB 43.1248 
Tyr 182 H132 3.2652 CB 43.1248 
Tyr 182 HD1 6.7909 CD1 132.8766 
Tyr 182 HD2 6.7909 CD2 132.8766 
Tyr 182 HE1 5.8431 CE1 117.1750 
Tyr 182 HE2 5.8431 CE2 117.1750 
182 HN 8.4401 N 116.1650 X 183 HA 5.8210 CA 55.5980 
Phe 183 HB1 2.6072 CB 42.8580 
Phe 183 H132 2.7491 CB 42.8580 
Phe 183 HD1 6.8329 CD1 131.2890 
Phe 183 HD2 6.8329 CD2 131.2890 
Phe 183 HE1 7.1909 CE1 131.2906 
Phe 183 HE2 7.1909 CE2 131.2906 
Phe 183 HZ 7.0812 CZ 129.2930 
Phe 183 HN 9.5078 N 118.9930 
Ser 184 HA 1.9046 CA 55.7342 
Ser 184 H131 3.2160 CB 62.6288 
Ser 184 HB2 3.8713 CB 62.6288 
Ser 184 HN 8.9092 N 119.1280 
Pro 185 HA 4.1151 CA 65.3240 
Pro 185 H131 1.8971 CB 31.2974 
Pro 185 H132 2.3197 CB 31.2974 
Pro 185 HD1 1.5622 CD 48.9806 
Pro 185 HD2 3.3169 CD 48.9806 
Pro 185 HG1 1.6860 CG 27.7541 
Pro 185 HG2 2.0900 CG 27.7541 
Ser 186 HA 4.4210 CA 58.1136 
Ser 186 HB1 3.8296 CB 63.4440 
Ser 186 HB2 4.0720 CB 63.4440 
Ser 186 HN -99 N -99 
Gly 187 HAl 3.4727 CA 45.3334 
Gly 187 HA2 4.2013 CA 45.3334 
Gly 187 HN 8.3280 N 112.1221 
Lys 188 HA 4.0781 CA 56.5146 
Lys 188 H131 1.4509 CB 32.9613 
Lys 188 H132 1.5486 CB 32.9613 
Lys 188 HD1 1.4226 CD 29.0072 
Lys 188 HD2 1.5503 CD 29.0072 
Lys 188 HE1 2.7587 CE 42.1728 
Lys 188 HE2 2.9568 CE 42.1728 
Lys 188 HG1 0.9118 CG 25.1375 
Lys 188 HG2 1.2175 CG 25.1375 
Lys 188 HN 7.5818 N 122.5470 
Lys 188 HZ1 -99 NZ -99 
Lys 188 HZ2 -99 NZ -99 
Lys 188 HZ3 -99 NZ -99 
Lys 189 HA 4.5237 CA 55.7323 
Lys 189 H131 1.4310 CB 35.1999 
Lys 189 H132 1.4310 CB 35.1999 
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Lys 189 HD1 1.1944 CL) 29.7534 
Lys 189 HD2 1.2146 CD 29.7534 
Lys 189 HE1 2.2298 CE 41.3606 
Lys 189 HE2 2.2298 CE 41.3606 
Lys 189 HG1 0.5641 CG 25.0340 
Lys 189 HG2 0.7263 CG 25.0340 
Lys 189 HN 8.0756 N 124.0375 
Lys 189 HZ1 -99 NZ -99 
Lys 189 HZ2 -99 NZ -99 
Lys 189 HZ3 -99 NZ -99 
Phe 190 HA 4.6884 CA 58.0154 
Phe 190 HB1 3.0134 CB 42.8819 
Phe 190 HB2 3.1861 CB 42.8819 
Phe 190 HD1 7.1748 CD1 131.5333 
Phe 190 HD2 7.1748 CD2 131.5333 
Phe 190 HE1 6.9820 CE1 131.5205 
Phe 190 HE2 6.9820 CE2 131.5205 
Phe 190 HZ 5.9041 CZ 129.4970 
Phe 190 HN 9.6003 N 124.2634 
Arg 191 HA 5.1408 CA 55.5985 
Arg 191 HB1 1.9961 CB 32.9257 
Arg 191 HB2 2.0789 CB 32.9257 
Arg 191 HD1 3.2216 CD 43.3637 
Arg 191 HD2 3.2216 CD 43.3637 
Arg 191 HG1 1.5672 CG 27.3634 
Arg 191 HG2 1.6837 CG 27.3634 
Arg 191 HN 9.1822 N 118.4686 
Arg 191 HE -99 NE -99 
Arg 191 HH11 -99 NH1 -99 
Arg 191 HH12 -99 NH1 -99 
Arg 191 HH21 -99 NH2 -99 
Arg 191 HH22 -99 NH2 -99 
Ser 192 HA 3.8897 CA 56.7478 
Ser 192 HB1 3.7786 CB 66.3836 
Ser 192 HB2 3.8735 CB 66.3836 
Ser 192 HN 7.7842 N 113.9360 
Lys 193 HA 4.0517 CA 61.4454 
Lys 193 HB1 1.9137 CB 30.1441 
Lys 193 HB2 2.0734 CB 30.1441 
Lys 193 HD1 1.6591 CD 30.2809 
Lys 193 HD2 1.6591 CD 30.2809 
Lys 193 HE1 3.1807 CE 43.3613 
Lys 193 HE2 3.1807 CE 43.3613 
Lys 193 HG1 1.4352 CG 26.7834 
Lys 193 HG2 1.4352 CG 26.7834 
Lys 193 HN 8.9354 N 123.0943 
Lys 193 HZ1 -99 NZ -99 
Lys 193 HZ2 -99 NZ -99 
Lys 193 HZ3 -99 NZ -99 
Pro 194 HA 4.3574 CA 66.1382 
Pro 194 HB1 1.7874 CB 31.0173 
Pro 194 HB2 2.3422 CB 31.0173 
Pro 194 HD1 3.6975 CD 49.8194 
Pro 194 HD2 3.7455 CD 49.8194 
Pro 194 HG1 1.9231 CG 28.5886 
Pro 194 HG2 2.1379 CG 28.5886 
Gin 195 HA 4.1426 CA 58.9625 
Gin 195 HB1 2.3044 CB 29.2231 
Gin 195 HB2 2.5618 CB 29.2231 
Gin 195 HG1 2.5362 CG 33.6748 
Gin 195 HG2 2.7205 CG 33.6748 
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Gin 195 HN 7.1506 N 115.8271 
Gin 195 HE21 6.8275 NE2 112.6522 
Gin 195 HE22 7.7664 NE2 112.6522 
Leu 196 HA 3.7396 CA 58.0679 
Len 196 HB1 1.5407 CB 43.6004 
Len 196 H132 1.7966 CB 43.6004 
Len 196 HD11 0.1129 CD1 25.5584 
Len 196 HD12 0.1129 CD1 25.5584 
Len 196 HD13 0.1129 CD1 25.5584 
Len 196 HD21 0.1503 CD2 -99 
Len 196 HD22 0.1503 CD2 -99 
Len 196 HD23 0.1503 CD2 -99 
Len 196 HG 1.1158 CG 26.6625 
Len 196 HN 7.8744 N 122.4750 
Ala 197 HA 3.9554 CA 54.5540 
Ala 197 H131 1.3627 CB 18.3397 
Ala 197 H132 1.3627 CB 18.3397 
Ala 197 H133 1.3627 CB 18.3397 
Ala 197 HN 8,9436 N 120.2710 
Arg 198 HA 4.0634 CA 58.7473 
Arg 198 HB1 1.9788 CB 30.3463 
Arg 198 H132 1.9831 CB 30.3463 
Arg 198 HD1 3.2491 CD 43.5481 
Arg 198 HD2 3.2956 CD 43.5481 
Arg 198 HG1 1.6967 CG 27.7650 
Arg 198 HG2 1.8396 CG 27.7650 
Arg 198 HN 7.9443 N 117.9353 
Arg 198 HE -99 NE -99 
Arg 198 HH11 -99 Nh -99 
Arg 198 HH12 -99 NH1 -99 
Arg 198 HH21 -99 NH2 -99 
Arg 198 HH22 -99 NH2 -99 
Tyr 199 HA 4.3200 CA 61.1987 
Tyr 199 HB1 2.8519 CB 40.3927 
Tyr 199 HB2 3.3992 CB 40.3927 
Tyr 199 111)1 7.1804 CD1 133.4910 
Tyr 199 HD2 7.1804 CD2 133.4910 
Tyr 199 HE1 7.0829 CE1 118.3859 
Tyr 199 HE2 7.0829 CE2 118.3859 
Tyr 199 HN 7.4993 N 119.2890 
Leu 200 HA 4.0354 CA 56.2165 
Leu 200 HB1 1.1551 CB 42.8975 
Leu 200 H132 1.6517 CB 42.8975 
Len 200 HD11 0.0298 CD1 25.7551 
Leu 200 HD12 0.0298 CD1 25.7551 
Leu 200 HD13 0.0298 CD1 25.7551 
Len 200 HD21 0.7593 CD2 23.4558 
Leu 200 HD22 0.7593 CD2 23.4558 
Len 200 HD23 0.7593 CD2 23.4558 
Leu 200 HG 1.4399 CG 27.5311 
Len 200 HN 8.1998 N 117.6693 
Giy 201 HAl 3.7476 CA 45.8535 
Giy 201 HA2 3.9738 CA 45.8535 
Giy 201 HN 7.7981 N 125.7620 
Asn 202 HA 4.5078 CA 53.7890 
Asn 202 HB1 2.8064 CB 38.1427 
Asn 202 HB2 2.8064 CB 38.1427 
Asn 202 HN 8.5099 N 118.1341 
Asn 202 HD21 6.9203 ND2 112.4569 
Asn 202 HD22 7.6186 ND2 112.4569 
Ala 203 HA 4.1326 CA 54.0093 
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Ala 203 HB1 1.4149 GB 19.3647 
Ala 203 HB2 1.4149 GB 19.3647 
Ala 203 HB3 1.4149 GB 19.3647 
Ala 203 HN 7.9741 N 121.1421 
Val 204 HA 4.0569 GA 60.2407 
Val 204 HB 1.6617 GB 34.4857 
Val 204 HG11 0.5401 GG1 21.3147 
Val 204 HG12 0.5401 CG1 21.3147 
Val 204 HG13 0.5401 GG1 21.3147 
Val 204 HG21 0.6438 CG2 21.0770 
Val 204 HG22 0.6438 CG2 21.0770 
Val 204 HG23 0.6438 CG2 21.0770 
Val 204 HN 7.0464 N 113.7798 
Asp 205 HA 4.6284 CA 53.2282 
Asp 205 HB1 2.5805 GB 40.6151 
Asp 205 HB2 2.8140 CB 40.6151 
Asp 205 HN 8.4176 N 124.0635 
Leu 206 HA 4.3709 GA 53.5287 
Leu 206 HB1 1.6119 GB 41.4044 
Leu 206 HB2 1.6119 GB 41.4044 
Leu 206 HD11 -0.0303 GD1 22.2246 
Leu 206 HD12 -0.0303 GD1 22.2246 
Leu 206 HD13 -0.0303 GD1 22.2246 
Leu 206 HD21 0.3633 CD2 25.7720 
Leu 206 HD22 0.3633 CD2 25.7720 
Leu 206 HD23 0.3633 CD2 25.7720 
Leu 206 HG 1.3819 GG 25.9936 
Leu 206 HN 9.1064 N 126.8948 
Ser 207 HA 4.0672 GA 63.1760 
Ser 207 HB1 3.8828 GB 62.3925 
Ser 207 HB2 3.9468 GB 62.3925 
Ser 207 HN 8.8169 N 120.7305 
Ser 208 HA -99 CA -99 
Ser 208 HB1 -99 GB -99 
Ser 208 HB2 -99 GB -99 
Ser 208 HN 8.7583 N 115.9256 
Phe 209 HA 4.3680 GA 53.5240 
Phe 209 HB1 1.6122 CB 41.2111 
Phe 209 HB2 2.6800 GB 41.2111 
Phe 209 HD1 -99 GD1 -99 
Phe 209 HD2 -99 CD2 -99 
Phe 209 HE1 -99 GEl -99 
Phe 209 HE2 -99 CE2 -99 
Phe 209 HZ -99 GZ -99 
Phe 209 HN 7.5276 N 123.6590 
Asp 210 HA 4.6580 GA 52.8045 
Asp 210 HB1 2.3230 GB 41.8540 
Asp 210 HB2 2.8718 GB 41.8540 
Asp 210 HN -99 N -99 
Phe 211 HA 3.6177 CA 61.6238 
Phe 211 HB1 2.9406 CB 41.3836 
Phe 211 HB2 3.2426 GB 41.3836 
Phe 211 HD1 7.0113 CD1 131.7530 
Phe 211 HD2 7.0113 CD2 131.7530 
Phe 211 HE1 7.2400 GEl 131.7851 
Phe 211 HE2 7.2400 GE2 131.7851 
Phe 211 HZ -99 CZ -99 
Phe 211 HN 8.9423 N 127.9309 
Arg 212 HA 4.0367 GA -99 
Arg 212 HB1 1.9272 GB 29.8990 
Arg 212 HB2 2.0018 GB 29.8990 
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Arg 212 HD1 3.2650 CD 42.8715 
Arg 212 HD2 3.2650 CD 42.8715 
Arg 212 HG1 1.6600 CG 27.7567 
Arg 212 HG2 1.7789 CG 27.7567 
Arg 212 HN 8.4421 N 114.7382 
Arg 212 HE 7.0000 NE -99 
Arg 212 Hill -99 NH1 -99 
Arg 212 HH12 -99 NH1 -99 
Arg 212 HH21 -99 NH2 -99 
Arg 212 HH22 -99 NH2 -99 
Thr 213 HA 4.2737 CA 61.7790 
Thr 213 HB 4.1275 CB 70.8670 
Thr 213 HG21 1.1258 CG2 53.2810 
Thr 213 HG22 1.1258 CG2 53.2810 
Thr 213 HG23 1.1258 CG2 53.2810 
Thr 213 HN -99 N -99 
Gly 214 HAl 3.7067 CA 47.4420 
Gly 214 HA2 3.8297 CA 47.4420 
Gly 214 HN 8.3153 N 114.1023 
Lys 215 HA 4.4440 CA 54.2600 
Lys 215 HB1 1.4826 CB 35.4457 
Lys 215 HB2 1.6980 CB 35.4457 
Lys 215 HD1 1.5823 CD 29.1283 
Lys 215 HD2 1.6223 CD 29.1283 
Lys 215 HE1 2.9564 CE 42.1463 
Lys 215 HE2 2.9564 CE 42.1463 
Lys 215 HG1 1.2821 CG 24.8049 
Lys 215 HG2 1.2821 CG 24.8049 
Lys 215 HN -99 N -99 
Lys 215 HZ1 -99 NZ -99 
Lys 215 HZ2 -99 NZ -99 
Ls 215 HD -99 NZ -99 
Yt 216 HA 4.6937 CA 54.0994 
Met 216 HB1 1.9172 CB 31.9149 
Met 216 HB2 2.0003 CB 31.9149 
Met 216 HE1 -99 CE -99 
Met 216 HE2 -99 CE -99 
Met 216 HE3 -99 CE -99 
Met 216 HG1 2.6168 CG 32.7207 
Met 216 HG2 2.6906 CG 32.7207 
Met 216 HN 8.5844 N 118.9710 
Met 217 HA 4.7957 CA 53.0304 
Met 217 HB1 1.9552 CB 32.2100 
Met 217 HB2 2.0739 CB 32.2100 
Met 217 HE1 -99 CE -99 
Met 217 HE2 -99 CE -99 
Met 217 HE3 -99 CE -99 
Met 217 HG1 2.4938 CG 32.2076 
Met 217 HG2 2.5902 CG 32.2076 
Met 217 HN 8.5628 N 124.5046 
Pro 218 HA 4.4149 CA 63.1740 
Pro 218 HB1 1.8936 CB 32.1998 
Pro 218 HB2 2.2936 CB 32.1998 
Pro 218 HD1 3.6678 CD 50.6137 
Pro 218 HD2 3.7657 CD 50.6137 
Pro 218 HG1 2.0071 CG 27.4993 
Pro 218 HG2 2.0071 CG 27.4993 
Ser 219 HA 4.3589 CA 58.4715 
Ser 219 HB1 3.8203 CB 63.9173 
Ser 219 HB2 3.8556 CB 63.9173 
Ser 219 HN 8.4666 N 116.6190 
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Lys 220 HA 4.2860 CA 56.3410 
Lys 220 H131 1.7220 GB 33.1140 
Lys 220 HB2 1.8340 GB 33.1140 
Lys 220 HD1 1.6490 CD 29.1500 
Lys 220 HD2 1.6490 CD 29.1500 
Lys 220 HE1 -99 GE -99 
Lys 220 HE2 -99 CE -99 
Lys 220 HG1 1.4100 GG 24.6880 
Lys 220 HG2 1.4100 CG 24.6880 
Lys 220 HN 8.4492 N 123.4920 
Lys 220 HZ1 -99 NZ -99 
Lys 220 HZ2 -99 NZ -99 
Lys 220 HD -99 NZ -99 
Leu 221 HA 4.2947 GA 55.1633 
Len 221 HB1 1.5701 GB 42.3704 
Len 221 HB2 1.5701 GB 42.3704 
Len 221 HD11 0.8397 GD1 23.4814 
Len 221 HD12 0.8397 GD1 23.4814 
Len 221 HD13 0.8397 CD1 23.4814 
Len 221 HD21 0.8994 GD2 24.8087 
Len 221 HD22 0.8994 GD2 24.8087 
Len 221 HD23 0.8994 CD2 24.8087 
Len 221 HG 1.5698 CG 27.0150 
Len 221 HN 8.2052 N 122.9260 
Gin 222 HA 4.3022 GA 55.5958 
Gin 222 HB1 1.9636 GB 29.5072 
Gin 222 H132 2.0708 GB 29.5072 
Gin 222 HG1 2.3301 CG 33.7073 
Gin 222 HG2 2.3301 CG 33.7073 
Gin 222 HN 8.3162 N 121.9090 
Gin 222 HE21 6.8920 NE2 113.0222 
Gin 222 HE22 7.6102 NE2 113.0222 
Lys 223 HA 4.3022 GA 56.2820 
Lys 223 HB1 1.7223 GB 33.1155 
Lys 223 HB2 1.8333 GB 33.1155 
Lys 223 HD1 1.6585 CD 29.1421 
Lys 223 HD2 1.6585 CD 29.1421 
Lys 223 HE1 2.9672 CE 42.1227 
Lys 223 HE2 2.9672 GE 42.1227 
Lys 223 HG1 1.4015 CG 24.6904 
Lys 223 HG2 1.4253 CG 24.6904 
Lys 223 HN 8.4287 N 123.9314 
Lys 223 HZ1 -99 NZ -99 
Lys 223 HZ2 -99 NZ -99 
Lys 223 HD -99 NZ -99 
Asn 224 HA 4.4540 CA 54.7660 
Asn 224 HB1 2.6476 GB 40.3766 
Asn 224 HB2 2.7524 GB 40.3766 
Asn 224 HN 8.1439 N 125.8620 
Asn 224 HD21 6.8440 ND2 113.0265 
Asn 224 HD22 7.5483 ND2 113.0265 
Table G.1: Table of mean chemical shifts of the MBD2 
MBD, based on all spectra. "-99" indicates that the atom 





A complete list of all the SPR data for systems in which binding constants could 
be measured. 
MBD ka (M's') kd (s') KA (M-') KD (M) x2  
MBD21  8.0x104 0.023 3.5x106 2.9x10 7 0.38 
MBD22  7.3x104  0.024 3.1x106 3.2x10 7 0.28 
MeCP21  1.5x106 0.040 3.6x107 2.75x10 8 1.04 
MeCP22  1.4x106 0.045 3.1x107 3.2x10 8 0.66 
MBD41  7.6x105 0.054 1.4x107 7.2x10 8 0.87 
MBD42  2.0x106 0.066 3.0x107 3.4x10 8 0.42 
Table D.1: Analysis of binding to mel2mer. 
MBD ka (M's') kd (s') KA (M-') KD (M) x2  
MBD21  4.7x104  0.015 3.1x106 3.2x10 7 0.63 
MBD22  5.0x104  0.016 3.1x106 3.2x10 7 0.38 
MeCP21  9.4x105  0.013 7.3x107 1.4x10 8 2.45 
MeCP22  9.4x105  0.013 7.1x107 1.4x10 8 1.96 
MBD41  1.5x106 0.05 3.0x107 3.4x10 8 0.53 
MBD42  1.5x106 0.05 2.8x107 3.5x10 8 0.44 
Table D.2: Analysis of binding to hernil2mer. 
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MBD ka (M's') kd (s 1 ) KA (M 1) KD (M) x2  
MBD21  3.0x104  0.013 2.4x106 4.2x10 7 0.35 
MBD22  2,9x104  0.013 2.2x106 4.6x10 7 0.33 
MeCP21  5.1x105  0.016 3.2x107 3.1x10 8 3.1 
MeCP22  4.6x105  0.016 2.9x107 3.4x10 8 2.8 
MBD41  1.3x106 0.038 3.4x107 3.0x10 8 1.1 
MBD42  1.0x106 0.040 2.5x107 4.0x10 8 0.8 
Table D.3: Analysis of binding to T12mer. 













Table D.4: Analysis of binding to melOmer. 
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